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ABSTRACT OF THESIS ENTITLED 
 
Generation of Hepatocyte-like cells from Mouse Embryonic Stem (ES) and Bone 
Marrow (BM) Cells 
 
The paucity of hepatocytes available for hepatocyte replacement therapy requires 
consideration of alternatives such as embryonic stem (ES) cell-derived hepatic 
progenitors or BM cells. Here, Green fluorescent protein (GFP) was knocked into the a-
fetal protein (AFP) locus of mouse ES cells to facilitate isolation of AFP+ hepatocyte-like 
progenitors that differentiated into hepatocyte-like cells in vivo and expressed albumin, 
haptoglobin and apolipoprotein-E. In addition, intrasplenic transplantation of BM cells in 
mouse models of hepatic deficiency can generate hepatocyte-like cells at low frequency. 
These cells can be amplified to a therapeutic level when given a selective advantage over 
host hepatocytes in a sufficiently chronic hepatic deficient microenvironment. This thesis 
proposes that both ES cells and BM are viable alternative cell sources in the cell 
replacement therapy for liver diseases.  
 
Keywords: hepatocytes, Embryonic Stem Cells, Bone Marrow, transplantation  
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General Statement 
1. Liver development 
The liver is the first glandular structure that differentiates in mammal embryonic 
development. It develops and originates from endodermal germ layer. The endoderm 
germ layer derives from the epiblast during gastrulation. It differs from the visceral 
endoderm, which arises from a non-embryonic lineage. It is called the definitive 
endoderm, which initially lines the ventral surface of the embryo (Zaret 2001). Anterior 
and posterior invaginations of definitive endoderm subsequently develop the embryonic 
foregut and hindgut pockets, from day 7.5 to 8.5 of embryonic gestation (E7.5-8.5) of the 
mouse (Zaret 2001). The anterior-ventral domain of the foregut endoderm, from E8.5-9.5, 
develops buds for the liver. This outgrowing bud of proliferating endodermal cells present 
in the ventral floor of the foregut can be identified morphologically in development of 
liver (Duncan 2003). After E7.5, the mesoderm exposed to endoderm can instruct 
endoderm to form anterior/posterior patterning and make endoderm competent to become 
hepatic cells by express several hepatic markers (Zaret 2000). By E8.5, fibrolast growth 
factor 1 (FGF1) and FGF2 from cardiac mesoderm can induce the foregut endoderm to 
the hepatic lineage (Jung, Zheng et al. 1999). By E9-10, bone morphogenetic proteins 
(BMPs) from septum transversum mesenchyme induce the liver specific transcription 
factor, GATA4, in the foregut endoderm prior to hepatogenesis (Rossi, Dunn et al. 2001). 
Both GATA4 and hepatocyte nuclear factor 3b  (HNF3b) are essential for hepatic 
specification and for downstream events leading to hepatocyte differentiation, such as 
inducing the expression of hepatocyte specific protein albumin (Ang, Wierda et al. 1993; 
Bossard and Zaret 1998; Rossi, Dunn et al. 2001). From E8.5 to 10.5, endothelial cells 
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between hepatic endoderm and septum transversum mesenchyme can mediate and induce 
liver bud cells to express albumin (Matsumoto, Yoshitomi et al. 2001). But the key 
factors from endothelial cells have not been identified yet. At E11.5, both hepatocyte 
growth factor (HGF) and its receptor cMet are detectable in the liver tissue. HGF can 
control the fetal liver cells proliferation and maturation (Sonnenberg, Weidner et al. 1993; 
Duncan 2003). At E14.5, oncostatin M (OSM) secreted by haematopoietic stem cells 
(HSCs) in liver has the effect on proliferation and maturation for fetal hepatocytes 
(Kinoshita, Sekiguchi et al. 1999). During embryonic development, it is crucial that the 
various differentiated hepatic cell types combine with extracellular components and 
connective tissues to generate a functional hepatic infrastructure (Duncan 2003). The 
process of differentiation of hepatoblast to hepatocyte is gradual, taking several days 
during the rodent embryo development. Electron microscopy of fetal rat tissues showed 
that the hepatoblast cells transit from an oblong shape at E12-14 to spherical around E18 
and finally become polygonal just prior to birth on E20 (Vassy, Kraemer et al. 1988). 
The liver accounts for one fiftieth of the total body weight in adult. It receives 
venous blood directly from the intestine, spleen and pancreas. As such, it encounters a 
diverse array of toxins, nutrients and hormones (Duncan 2003). Reflecting the anatomical 
and physiological properties, the liver performs endocrine functions that condition the 
blood through detoxification and the secretion of serum factors. In addition to its 
endocrine activity, the liver also exhibits an exocrine function through the generation of 
bile (Duncan 2003). In the cellular composition, approximately 60% of the cells in the 
adult rat liver are hepatocytes, while the remaining cells consist largely of cholangiocytes, 
Kuppfer cells, stellate cells, and a variety of endothelial cells including those lining the 
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sinusoid (sinusoidal endothelial cells) (Blouin, Bolender et al. 1977). The architecture of 
the liver is absolutely critical for normal liver function and is often severely affected 
during chronic liver injury (Friedman 2000). 
2. Causes and treatment of liver failure  
Serious liver disease has many causes, such as viral hepatitis, drug toxicity 
(paracetamol overdose), environmental toxin, alcohol, metastatic malignancy, inherent 
genetic defect, etc. The disease outcome generally depends on the extent of functional 
hepatic compromise and the ability of undamaged hepatocytes to replicate and replace 
diseased parenchyma with many cases progressing to end-stage liver failure when liver 
functional capacity drops below a critical level (Tilles, Berthiaume et al. 2002). In 
fulminant hepatitis, survival rate is 15-25% when treated with conservative medical 
measures. In most case, survival is measured in days and hours, and death in weeks 
(Bernuau, Rueff et al. 1986). Orthotopic liver transplantation remains the only established 
successful treatment to reverse the severe liver dysfunction and terminal liver failure. 60-
75% of liver failure can be rescued by liver transplantation (Lidofsky 1993). 
Unfortunately, this treatment has severe limitations such as tissue compatibility, size 
discrepancy, use of medication, age, preexistent disease, and most notably, the paucity of 
liver donors. Therefore, mortality rates for liver failure remain high. 
Many devices including bio-artificial liver device have been developed in order to 
provide temporary liver support for patients with acute liver failure to either allow liver 
regeneration or await liver transplantation. Unfortunately, to date, these systems have not 
been able to improve the clinical status of the patient with liver failure (Tilles, 
Berthiaume et al. 2002). Furthermore, the use of hepatoma cell lines or porcine 
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hepatocytes in some of bio-artificial liver devices raises the possibility of side effects like 
transmigration of tumor cells to patients or pig-to-human transmission of activated 
porcine endogenous retrovirus (PERV) (Stockmann and JN 2002). 
Recently, transplantation of a small number of genetically normal hepatocytes in 
both animal models (Braun, Degen et al. 2000) and human patients (Strom, Chowdhury et 
al. 1999) were shown to be sufficient in correcting liver disease caused by certain inborn 
errors of metabolism leading to the proposal that transplantation of healthy hepatocytes 
into diseased liver may be an alternative therapy (Gupta, Malhi et al. 1999). Under these 
circumstances, therapy may not require proliferation of donor cells but only their 
persistence. However, this procedure is also severely limited by a shortage of donor 
organs necessary for the isolation of human hepatocytes. Furthermore, this procedure is 
not suitable for patients requiring replacement of a large portion of the diseased 
parenchyma by donor cells as transplantation of a large number of hepatocytes into the 
spleen or portal vein may cause portal hypertension and parenchymal ischemia (Braun, 
Degen et al. 2000). Therefore, it was suggested that for hepatocyte or cell transplantation 
to be a viable therapeutic option to replace sufficient liver parenchyma in the treatment of 
liver diseases, proliferation of donor cells after transplantation is a necessary prerequisite 
and in this regard, hepatic stem cells and/or progenitor cells are ideal candidates.  
3. Particular cell response to different liver injury 
The restitutive response of the liver to different injuries involves proliferation of 
cells at different levels in the liver lineage. It was postulated recently that there are three 
levels of proliferating cells in the liver (Sell 2001). First is mature hepatocyte. In the 
classic partial hepatectomy (PH´) experiment, the loss of two thirds of the rat liver is 
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replaced by proliferation of hepatocytes. 95% of the hepatocytes of young animals 
replicate between 12 to 48 hours in rat and 30 to 60 hours in mice (Fausto and Campbell 
2003). The mature hepatocytes have “unlimited” replicative potential on damage liver 
repopulation (Rhim, Sandgren et al. 1994; Overturf, Al-Dhalimy et al. 1996). There was 
little or no evidence of involvement of a liver stem cell (Sell 2001; Fausto and Campbell 
2003). The second is intrahepatic stem cell. The canals of Hering in anatomic liver 
architecture presumably constitute the stem cel niche in adult liver. The presumed 
progeny of stem cells, oval cells, are not detectable in normal liver but abundantly 
proliferate, probably as an amplifying transit compartment after stem cell activation. This 
cell proliferation is prominent in many models of liver injury including carcinogenesis 
(azo-dyes, etc), injury caused by D-galactosamine, dipin, etc (Sell 2001). These cells are 
immunoreactive to a-fetal protein (AFP), and to antibodies generally associated with 
haematopoietic lineage, such as Thy-1, CD34 and c-kit (Omori, Evarts et al. 1997; Omori, 
Omori et al. 1997; Petersen, Goff et al. 1998). There is still another type of cell referred to 
as “small hepatocytes” (small hepatocyte-like progenitor cell or SHPC) that is apparently 
responsible for the regeneration of rat liver after PH in animals exposed to retrorsine 
(Gordon, Coleman et al. 2000; Gordon, Coleman et al. 2000). SHPCs express some 
hepatocyte markers but represent a less differentiated population that is phenotypically 
distinct from hepatocytes (Gordon, Coleman et al. 2000). The location of these cells in 
the liver is unknown at this time. The third is a multipotent stem cell in the liver derived 
from circulating bone marrow (BM) stem cells. Since the oval cells and hepatocytes from 
HSCs can be generated (Petersen, Bowen et al. 1999; Alison, Poulsom et al. 2000; 
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Theise, Badve et al. 2000). The capacity of haematopoietic stem cell (HSC) to generate 
cellular lineages in the adult liver is an arguing subject currently.  
4. Definition and classification of stem cells 
What is a stem cell? A stem cell is a cell from the embryo, fetus, or adult that has, 
under certain conditions, the abilities to self-renew and to give rise to specialized cells 
that make up the tissues and organs of the body. In general, there are three types of stem 
cells defined by their origins. 
An embryonic stem (ES) cell is an undifferentiated, and pluripotent cell derived 
from the inner cell mass of blastocyst (Evans and Kaufman 1981; Martin 1981). The first 
ES cell cultures to be established were murine ES cells. They have two distinguishing 
features. When cultured on feeder-cell layers of mouse embryonic fibroblasts, or in the 
presence of leukemia inhibitory factor (LIF), ES cells maintain their undifferentiated 
phenotype and unlimited self-renewal capacity. Removal of the feeder-cell layer and 
withdrawal of LIF induce spontaneous differentiation of ES cells into cells representative 
of all three germ layers. When transplanted into an early embryo, they can contribute to 
all somatic cells of the embryo and germ cells, but not to the placental tissue (Bradley, 
Evans et al. 1984). In 1995, ES cells from nonhuman primates were isolated (Thomson, 
Kalishman et al. 1995). The derivation of human ES cell lines followed shortly 
(Thomson, Itskovitz-Eldor et al. 1998; Reubinoff, Pera et al. 2000).  
The second type of stem cell is embryonic germ (EG) cells isolated from the 
primordial germ cells of the gonadal ridge of the fetus (Matsui, Zsebo et al. 1992). In 
most aspects, they are indistinguishable from blastocyst-derived ES cells. Mouse EG cells 
when transferred into blastocysts can efficiently form chimeras and contribute to germline 
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(Labosky, Barlow et al. 1994; Stewart, Gadi et al. 1994). Derivation of human EG cells 
from aborted fetus has also been reported (Shamblott, Axelman et al. 1998). 
The third type of stem cell is the adult stem cells. Like ES and EG cells, adult stem 
cells can self-renew, but unlike ES and EG cells, they give rise to specific sets of mature 
cell types. Adult stem cells have been found in many adult tissues e.g. bone marrow 
(BM), brain, epithelia of the skin and digestive system, etc. 
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Part I AFP+, ES Cell-Derived Cells Engraft and Differentiate 
into Hepatocyte-like cells in vivo 
Abstract 
The self-renewal ability and pluripotency of embryonic stem (ES) cell have made 
it a potential source of cells for stem cell transplantation, gene therapy and tissue 
engineering. However, differentiating ES cells into specific tissue stem cells or cell types 
remains a major challenge in practical applications of ES cells. To isolate putative liver-
specific progenitor cells, a green fluorescent protein (GFP) gene was inserted into the a-
fetoprotein (AFP) locus of ES cells by homologous recombination such that after 
differentiation, differentiated ES cells that expressed AFP will also express GFP. These 
differentiated cells were isolated by fluorescence-activated cell sorting (FACS), and 
transplanted intrasplenically into partially hepatectomized (PHx) lacZ-positive ROSA26 
mice, apolipoprotein-E (ApoE)- or haptoglobin (Hp)- deficient mice. We demonstrated by 
immunohistochemistry that these AFP+/GFP+ cells engrafted and differentiated into 
albumin- and ApoE-positive hepatocytes. In Hp- and ApoE-deficient mice, these cells 
differentiated into Hp- and ApoE-positive hepatocytes that secreted Hp or ApoE protein 
into serum, respectively. In conclusion, our experiments demonstrated that hepatocyte-
like progenitor cells could be purified from in vitro differentiated ES cells using AFP as a 
marker, and these cells can differentiate into hepatocyte-like cells with some hepatocyte 
functions in vivo. (Yin Y, Lim YK, Salto-Tellez M, Ng SC, Lin CS and Lim SK. Stem 
Cells 2002; 20:338-346) 
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1 Introduction 
1.1 General statement 
The differentiation potential of murine ES cells both in vivo and in vitro is well 
documented. They can differentiate in vivo and in vitro into a mixture of endodermal, 
ectodermal and mesodermal cell lineages such as cardiomyocyte, endothelial cells, 
neuron, astrocytes, etc (Doetschman, Eistetter et al. 1985; Wiles and Keller 1991; Keller, 
Kennedy et al. 1993).  In vitro, they form embryoid bodies (EBs) in a manner that closely 
recapitulates early development of mouse embryo in a temporal and spatial manner 
(Keller 1995; Leahy, Xiong et al. 1999). Therefore, this pluripotent cell line provide a 
tremendous resource for studies in developmental biology; moreover, it has the potential 
to generate an unlimited supply of cells for cell transplantation and gene therapy (O'Shea 
1999).  
1.2 Generation and experimental application of ES cell derivatives 
Much progress has been made to advance the use of ES cells as a source for cell 
replacement therapy (Daley 2002). Using animal models, ES cell derivatives have been 
used to form mesodermal tissues e.g. hematopoietic system and cardiomyocyte (Hassink, 
Brutel de la Riviere et al. 2003), and ectodermal tissues e.g neural system (Stavridis and 
Smith 2003). In the derivation of mesodermal tissues from ES cells, much of the efforts 
were focused on the derivation of hematopoietic lineages. A large number of studies has 
documented the generation of primitive and definitive (adult) erythroid, myeloid and 
lymphoid lineages from ES cells in vitro (Gutierrez-Ramos and Palacios 1992; Keller, 
Kennedy et al. 1993; Nakano, Kodama et al. 1994; Lieschke and Dunn 1995; Nakano 
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1996). The use of ES cell-derived cells in repopulating hematopoiesis in vivo was 
generally ineffective (Gutierrez-Ramos and Palacios 1992; Muller and Dzierzak 1993; 
Nisitani, Tsubata et al. 1994) until recently. In 2002, it was demonstrated that ES cell-
derived cells with ectopic expression of HoxB4 engrafted in lethally irradiated adult 
mouse and contributed to long-term, multilineage hematopoiesis in mice (Kyba, 
Perlingeiro et al. 2002). Interestingly, like murine ES cells, human ES cells upon co-
culture with a murine BM cell line or yolk sac endothelial cell line, can also generate 
myeloid, erythroid, megakaryocyte and multipotential colony-forming cells (CFCs) 
(Kaufman, Hanson et al. 2001; Kaufman and Thomson 2002). Therefore, human ES cells 
can also be used as a research tool to better understand human hematopoiesis and as a 
source of hematopoietic cells for transfusion and transplantation therapies. 
Another ES cell-derived mesodermal lineage of clinical significance is the 
cardiomyocytes. Ischaemic heart disease is the leading cause of morbidity and mortality 
in the world. Cardiomyocyte transplantation may prevent or limit post-infarction cardiac 
failure (Hughes 2002). It has been shown that mouse ES cells could spontaneously 
differentiate into beating cardiomyocytes (Doetschman, Eistetter et al. 1985), which were 
found to represent phenotypes corresponding to atrium or ventricle of the heart (Maltsev, 
Rohwedel et al. 1993). Using genetic manipulation of mouse ES cells, relatively pure 
cardiomyocytes were generated and successfully engrafted in the hearts of adult 
dystrophic mice (Klug, Soonpaa et al. 1996). More importantly, human ES cells can also 
efficiently generate functional cardiomyocytes with expression of markers characteristic 
of cardiomyocytes (Mummery, Ward et al. 2002; Xu, Police et al. 2002), providing a 
promising approach for the treatment of damaged cardiac tissue in practical application.  
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A third therapeutically important mesodermal lineage that has been a major target in 
ES cell differentiation is the endothelial lineage. Endothelial cells as defined by specific 
uptake of acetylated LDL, the presence of von Willebrand's factor, expression of Flk1, a 
receptor for vascular endothelial growth factor (VEGF) have been derived from in vitro 
differentiation of mouse (Risau, Sariola et al. 1988; Wang, Clark et al. 1992; Bautch, 
Stanford et al. 1996; Yamashita, Itoh et al. 2000), primate (Sone, Itoh et al. 2003), and 
human ES cells (Levenberg, Golub et al. 2002). 
Other mesodermal derivatives that have reportedly been derived from ES cells 
include skeletal muscle (Rohwedel, Maltsev et al. 1994), smooth muscle (Yamashita, Itoh 
et al. 2000), adipocytes (Dani, Smith et al. 1997), osteoblasts (Buttery, Bourne et al. 
2001) and chondrocytes (Kramer, Hegert et al. 2000). These results illustrate the potential 
of ES cells in tissue engineering involving mesodermal tissues. 
 
ES cells have also been shown to differentiate into ectodermal cells like neurons, 
oligodendrocytes, astrocytes (Stavridis and Smith 2003), epithelial cells and keratinocytes 
(Bagutti, Wobus et al. 1996) and melanocytes (Yamane, Hayashi et al. 1999). For obvious 
reasons, much attention has been focused on producing neural cells. In 1995, several 
reports showed that ES cells can differentiate into astrocytes, oligodendrocytes 
(Fraichard, Chassande et al. 1995), and neuron-like cells with the capability of generating 
action potentials, voltage-gated potassium and calcium channels, and receptor-operated 
ionic channels (Bain, Kitchens et al. 1995; Strubing, Ahnert-Hilger et al. 1995). Further 
experiments demonstrated that ES cell-derived neural precursors could engraft, migrate 
and differentiate into neurons, astrocytes, and oligodendrocytes in telencephalic, 
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diencephalic, and mesencephalic regions of the host brain when transplanted into the 
developing rat embryo (Brustle, Spiro et al. 1997). When transplanted into rat model of 
human myelin disease or in the spinal cords of myelin-deficient mutant mice, ES cell-
derived precursors for oligodendrocytes and astrocytes could interact with host neurons 
and myelinate host axons in brain and spinal cord (Brustle, Jones et al. 1999; Liu, Qu et 
al. 2000). It is likely that ES cell-derived cells could improve locomotor function in 
acutely injured spinal cord in rat (McDonald, Liu et al. 1999). More recently, it was 
reported that ES cells can generate dopaminergic (DA) and serotonergic neurons in vitro 
(Lee, Lumelsky et al. 2000) and these ES cell-derived dopaminergic neurons are 
functional in a rat model of Parkinson's disease (Kim, Auerbach et al. 2002).  
The derivation of human ES cell lines and more importantly, the recent generation 
of human ES cell-derived neural progenitors suggests that the use of human ES cells for 
the treatment of neurological disorders is a realistic possibility. It was demonstrated that 
human ES cell-derived neural progenitors can differentiate in vitro into three fundamental 
neural lineages, astrocytes, oligodendrocytes and neurons; moreover, they can participate 
in newborn mouse brain development after transplantation into ventricles (Reubinoff, 
Itsykson et al. 2001; Zhang, Wernig et al. 2001).  
 
Although it is well documented that endodermal specific marker genes, such as 
alpha-fetoprotein (AFP), hepatocyte nuclear factor 3b  (HNF3b), and albumin, are 
expressed during ES cell differentiation, suggesting that ES cells can differentiate into 
endodermal tissues (Meehan, Barlow et al. 1984; Doetschman, Eistetter et al. 1985; Abe, 
Niwa et al. 1996), generation and applications of ES cell-derived endodermal cells are not 
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as well studied as that for mesodermal and ectodermal lineages. Recently, it was reported 
that murine ES cells can differentiate to form a functional gut-like unit with 
characteristics of the gastrointestinal tract (Yamada, Yoshikawa et al. 2002). They can 
also generate cells expressing insulin and other pancreatic endocrine hormones (Soria, 
Roche et al. 2000; Lumelsky, Blondel et al. 2001) but these cells fail to cure diabetic 
mellitus after transplantation into diabetic mice (Lumelsky, Blondel et al. 2001). Like 
murine ES cells, it was reported that human ES cells can differentiate in vitro to form 
insulin-producing beta-like cells (Assady, Maor et al. 2001). However, Melton and his co-
workers proposed that the murine ES cell-derived “insulin-secreting” cells were 
experimental artifacts. They demonstrated that these cells took up insulin from the media 
and secreted it upon stimulation (Rajagopal, Anderson et al. 2003). Clearly, more studies 
are necessary to resolve this issue. Nevertheless, genetically modified ES cells e.g. ES 
cells with constitutive expression of Pax4 can be induced to differentiate to form insulin-
producing cells which normalize blood glucose level after transplantation into 
streptozotocin-treated diabetic mice (Blyszczuk, Czyz et al. 2003).  
ES cells were also shown to be able to differentiate in vitro into hepatocytes, 
another endodermal lineage. These ES cell-derived hepatocytes express mature 
hepatocyte properties e.g. tyrosine aminotransferase (TAT) and glucose-6-phosphatase 
(Hamazaki, Iiboshi et al. 2001), tryptophan-2,3-dioxygenase, urea  cycle enzyme, 
gluconeogenic enzyme, and liver-specific organic anion transporter-1 (Yamada, 
Yoshikawa et al. 2002) as well as endoderm specific genes such as AFP, a-1 antitrypsin 
(a-1 ATT), and albumin (Hamazaki, Iiboshi et al. 2001; Chinzei, Tanaka et al. 2002; 
Yamada, Yoshikawa et al. 2002). After transplantation of these ES-derivatives, they are 
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morphologically indistinguishable from neighboring hepatocytes (Yamada, Yoshikawa et 
al. 2002), and accounted for 0.2% of total liver cells containing Y-chromosome and 
albumin (Chinzei, Tanaka et al. 2002).  
1.3 Challenges in isolating ES cell derivatives 
Although much progress has been made in using ES cell derivatives such as 
neuron, cardiomyocyte, beta cells to treat animal models of human diseases, there are still 
considerable obstacles in clinical applications of ES cells or their derivatives. Since 
transplanted ES cells will invariably result in the formation of teratoma, therapeutic use of 
ES cells in its undifferentiated state is highly limited (Doetschman, Eistetter et al. 1985; 
Keller, Kennedy et al. 1993). It is envisaged that therapeutic applications of ES cells will 
involve prior differentiation into specific cell types either as tissue-specific progenitor 
cells or as terminally differentiated cells. Therefore, two major challenges in ES cell 
research are the directed differentiation of ES cells along a specific lineage and the 
preparation of sufficiently homogenous tissue-specific cell type for therapeutic 
applications. Although ES cells can be induced to differentiate into all tissues from the 
three germ layers, the ability to direct its differentiation into a specific cell type remains 
elusive in spite of many efforts to identify and isolate factors required for lineage-specific 
differentiation. The strategy for purifying homogenous ES cell-derived tissue-specific 
cells in sufficient quantity for therapeutic applications has also been challenging. One 
limiting factor is the lack of reliable markers (Smith 2001).  
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1.4 Specific challenges in isolating ES-derived hepatic progenitor cells 
The challenge in isolating ES cell-derived hepatic progenitor cells is similar to the 
general challenges described above i.e. directed differentiation of ES cells into 
endodermal lineage and isolating hepatic progenitor cells. One approach is to express a 
selectable marker e.g. antibiotic resistance gene, and/or a reporter gene e.g. b-
galactosidase (b-gal) gene, or green fluorescent protein gene (GFP) (Klug, Soonpaa et al. 
1996; Li, Pevny et al. 1998; Soria, Roche et al. 2000) such  that the selectable marker or 
reporter gene is expressed only in the cell type of interest, either by using a tissue-specific 
promoter or by homologous recombination into an endogenous gene locus that express 
the gene in the tissue of interest.  
One ideal endogenous gene locus for expressing reporter gene in hepatic progenitor 
cells is the AFP locus. AFP is expressed in a tissue-specific manner during mammalian 
development. In early mouse embryos, AFP expression is specific to the visceral 
endoderm of the yolk sac and the gut endoderm before being restricted to the fetal liver 
and fetal gut later in development (Dziadek and Andrews 1983; Shiojiri, Lemire et al. 
1991; Gualdi, Bossard et al. 1996). AFP is one of the earliest proteins expressed in the 
hepatic lineage during embryonic development. AFP expression declines rapidly after 
birth, and the level of its mRNA in adult liver is less than 0.01% of that in fetal liver. 
During rapid hepatocyte proliferation such as liver regeneration or tumorigenesis, AFP 
expression is re-activated (Sell and Ilic 1997). AFP is also expressed in differentiating ES 
cells. The early embryonic expression pattern of AFP is essentially recapitulated during  
the development of ES cells into EBs (Doetschman, Eistetter et al. 1985; Abe, Niwa et al. 
1996; Morrisey, Tang et al. 1998). These results suggest that AFP expressing cells in 
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differentiated EBs could be endodermal progenitor cells that constitute a committed 
hepatic lineage during ES cell differentiation. 
1.5 The objectives of the study 
The purpose of this study is to identify hepatic progenitor cells using AFP as a 
selectable marker in a differentiated ES cell population. In this study, ES cells were 
genetically modified by knocking GFP gene into AFP locus so that GFP expression is 
under the regulatory control of AFP promoter. Therefore, any AFP+ cells will also be 
GFP+ and can then be easily isolated by FACS.  
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2 Materials and Methods  
2.1 Gene Targeting 
 The targeting construct for knocking the GFP gene into the AFP locus was a 
replacement type of vector designed to replace AFP coding sequences with those of GFP. 
The vector was designed to replace AFP coding sequences in exon 1 and exon 2 with 
those of GFP gene. The vector was generated by ligating the ATG start codon of AFP in-
frame to that of GFP gene. Prior to ligation, an NcoI site was created at the AFP start 
codon gene by converting the second translation codon from AAG to GAG. A plasmid 
vector with a GFP insert (Clontech Laboratories; Palo Alto, CA; 
http://www.clontech.com/index.shtml) was partially cleaved by NcoI-cleaved AFP DNA. 
The resulting hybrid gene was essentially a GFP gene flanked at the 5’ end by about 2kb 
of AFP genomic sequences. At the 3’ end, it was flanked by a loxP/PGK TK/PGK 
Neo/loxP (LTNL) fragment followed by 5 kb of AFP genomic sequences comprising 
exon 3 to exon 5. The construct was linearized with NotI and electroporated into CS-1 ES 
cells with the electropulser (Bio-Rad, http://www.bio-rad.com). CS-1 ES cell is a 129Sv-
derived cell line (a gift of C.S. Lin). Transfected cells were selected in the presence of 
G418. A HindIII/BamHI fragment derived from exon 6 and intron 6 of the AFP gene was 
used as probe for Southern Blot hybridization. Targeted ES cell clones (recombinant ES 
cells) were identified after HindIII digestion by Southern blot hybridization using this 
probe. 
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2.2 Maintenance of recombinant ES (rES) cell without differentiation 
rES cells were maintained in the presence of mitomycin C-treated mouse 
embryonic fibroblasts (MEFs) as feeder cells (Hogan, Beddington et al. 1994) or 
leukemia inhibitory factor (LIF) (100-1000u/ml) in the 0.1% gelatin-coated culture plate 
in ES medium [Dulbecco’s modified Eagle’s medium (DMEM) (GIBCO/BRL, 
Invitrogen, Grand Island, NY), 20% fetal bovine serum (FBS) (Hyclone, Logan, Utah), 
0.1mM 2-mercaptoethanol (Sigma; St. Louis, MO), 0.1mM nonessential amino acids 
(MEM) (GIBCO/BRL; Invitrogen, Grand Island, NY), 100u/ml penicillin, 100mg/ml 
streptomycin sulfate, and 292mg/ml L-glutamine (GIBCO/BRL, Invitrogen, Grand Island, 
NY). 
2.3 rES cell differentiation 
2.3.1 Differentiation in vitro using suspension culture method (Robertson 1987) 
Feeder-free rES cells were maintained in ES medium in the presence of LIF. 
Exponentially growing rES cells at 70-80% confluent were trypsinized by Trypsin/EDTA 
(GIBCO/BRL, Invitrogen, Grand Island, NY) for 8-10min in 37°C incubator. Cells were 
centrifuged at 400g for 5min. Then rES cells were resuspended at 106cells/ml in ES 
medium to form EB aggregates without addition of LIF. After 4 days, these EBs were 
transferred to a bacteriological Petri dish for further growing. Culture media were 
changed every day. At duration of 5, 8 and 12 days of suspension culture, transferred EBs 
were harvested and allowed to adhere to tissue culture slides for 2 hours before being 
fixed with 10% neutral buffered formalin (Sigma; St. Louis, MO) and viewing with 
microscopy (LSM510, Zeiss, Germany). 
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2.3.2 Differentiation in vitro using a modified two-step suspension culture method 
(Wiles 1993)  
Exponentially growing feeder-free rES cells were resuspended in IMDM (Iscove’s 
modified Dulbecco’s medium) (GIBCO/BRL; Invitrogen, Grand Island, NY, 
http://www.lifetech.com) at 2´105 cells/ml. 2´104 cells in 100 ml were plated into 10ml 
IMDM-based methylcellulose differentiation medium [0.9% methylcellulose (MethoCult 
M3134; StemCell Technologies, Inc; Canada; http://www.stemcell.com), 15% defined 
FBS (Hyclone, Logan, Utah), 0.44nM monothioglycerol (Sigma; St Louis, MO; 
http://www.sigmaaldrich.com), 100u/ml penicillin, 100mg/ml streptomycin sulfate, and 
292mg/ml L-glutamine (GIBCO/BRL; Invitrogen, Grand Island, NY)]. Six days later, the 
EBs were harvested by adding 2×10ml IMDM to each 10ml plate and centrifuging at 
400g for 5min. The EBs were washed in 2% FBS in PBS (8g NaCl, 0.2g KCl, 1.44g 
Na2HPO4, 0.24g KH2PO4, in 1 litre, pH7.4). They were dissociated into single cell 
suspension by incubation with 0.15% collagenase type IA (Sigma; St Louis, MO) in 2% 
FBS for 30-40min at 37ºC with shaking. Dissociated EBs were centrifuged, and 
resuspended in IMDM in 108cells/ml. 107 cells in 100ml were replated into 10ml IMDM-
based methylcellulose differentiation medium supplemented with or without Hepa-
conditioned medium (333ml per 10ml differentiation medium). The cells were incubated 
for another 6 days. The secondary EBs were harvested and dissociated into single cells as 
described above of collagenase digestion. The cell suspension were filtered by passing 
through 40mm size mesh (Becton Dickinson Labware, MA) resuspended at 107cells/ml in 
2% FBS solution and kept on ice for further analysis. 
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Hepa-conditioned medium were prepared from the media of Hepa cell cultures, a 
mouse hepatoma cell line. After growing 70-80% sub-confluent Hepa cell cultures in 
DMEM with 10% FBS for two days, the medium was harvested, centrifuged twice at 
800g for 5min to remove cellular debris, and filtered through a 0.2mm filter. This 
conditioned medium was stored in aliquots at -80°C. 
2.3.3 Analysis and assortment of GFP expressing cells in differentiated rES cells by 
FACS  
After differentiation using the two-step differentiation protocol, differentiated rES 
cells were harvested and dissociated as described above at day 6 (D6), D9, D12, D15, and 
D18. Samples were fixed in 2% paraformaldehyde, and stored at 4ºC until FACS analysis 
(FACStarplus; Becton Dickinson; San Jose, CA; http://www.bd.com). Sample without 
fixation was kept on ice for FACS sorting. GFP+, and/or GFP- cells were isolated and 
kept in ice for further analysis or transplantation. 
2.3.4 Fluorescent-microscope analysis of rES and D12 differentiated rES cells 
To verify the detection of GFP expression by FACS analysis, rES cells and D12 
differentiated rES cells were fixed in 2% paraformaldehyde, stained with propidium 
iodide (PI) and viewed with a fluorescent microscope. 
2.4 Partial Hepatectomy (PHx) and Cell Transplantation 
B6.129P2-ApoEtm1Unc (ApoE-deficient) mice (Piedrahita, Zhang et al. 1992), and 
B6.129S7-Gtrosa26 (Rosa26) mice were purchased from Jackson Laboratory (Bar 
Harbor, ME; http://www.jax.org). 129/Sv mice were purchased from Animal Resource 
Centre (Australia). Haptoglobin (Hp)-deficient mice were generated in the laboratory of 
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SK Lim (Lim, Kim et al. 1998). For transplantation of GFP+ cells, lacZ-positive F1 
hybrid mice from a cross between B6.129S7-Gtrosa26 and 129/Sv strains were used to 
prevent immune rejection of the transplanted cells. 
The ApoE mutated homozygous mice show a marked increase in total plasma 
cholesterol levels that are unaffected by age or sex. Fatty streaks in the proximal aorta are 
found at 3 months of age. The lesions increase with age and progress to lesions with less 
lipid but more elongated cells, typical of a more advanced stage of pre-atherosclerotic 
lesion. Moderately increased triglyceride levels have been reported in mice with this 
mutation on a mixed C57BL/6´129 genetic background. Recent studies indicate that 
ApoE deficient mice have altered responses to stress, impaired spatial learning and 
memory, altered long term potentiation, and synaptic damage. The primary role of ApoE 
protein is to transport cholesterol and triglycerides thoughout the body. ApoE is 
expressed most abundantly in the liver and brain (http://www.jax.org). 
Rosa26 mouse was produced by random retroviral gene trapping in ES cells 
(Zambrowicz, Imamoto et al. 1997). The pomoter is an unknown endogenous promoter. 
Although there is no apparent defect in heterozygous or homozygous Rosa26 mice, 
homozygotes were recovered in fewer pup numbers. In this mouse strain, the b-gal 
activity was demonstrated ubiquitously in various tissues and in the hematopoietic cells. 
Ubiquitous staining was found in the following tissues: brain, bone marrow, cartilage, 
heart, intestine, kidney, liver, lung, pancreas, muscle, skin, spleen, submandibular gland, 
thymus, trachea, urinary bladder, adult testis (Zambrowicz, Imamoto et al. 1997). This 
makes a useful marker in chimera and transplantation experiments (http://www.jax.org). 
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Homozygous haptoglobin mutant mice are viable and fertile, but theire viability 
was comparomised. They have a significant reduction in postnatal viability and an 
amelioration of tissue damages by hemoglobin-drived lipid peroxidation (Lim, Kim et al. 
1998). The major site of synthesis of haptoglobin is the liver (D'Armiento, Dalal et al. 
1997). 
In all the experiments, the regenerative environment is created by partial 
hepatectomy (PH´), which two-thirds of the liver is removed. PH´ is one of the best 
experimental models for the study of liver regeneration. Specific liver lobes are removed 
intact, without damage to the left lobes. The residual lobes enlarge to make up for the 
mass of the removed the lobes, though the resected lobes never grow back. The whole 
process takes 5 to 7 days. In comparison with other method, PH´ is not associated with 
tissue injury and inflammation, and the initiation of the regenerative stimulus is precisely 
defined (removal of liver lobes) (Michalopoulos and DeFrances 1997). As to cell 
transplantation, ES cell-derived GFP positive cells were transplanted through intrasplenic 
injection. Intrasplenic injection could prevent cell clumps from entering liver to form 
thombosis that causes the portal hypertension induced by direct infusion cells from portal 
vein. Spleen may serve as a positive filter so that the liver-preferential cells can be 
delivered to the liver by blood flow from spleen to liver.  Intrasplenic injection may also 
reduce bleeding induced by the direct infusion of cells from portal vein. However, 
intrasplenic transplantation only gives rise to about 21% of the hepatocyte engraft 
efficienc (Weglarz, Degen et al. 2000). 
Mice were anesthetized with 0.1ml per 10g body weight (bw) of a cocktail 
consisting of 1 part hypnorm, 1 part Midazolom and 2 parts distilled water. A transverse 
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abdominal incision of about 1 cm was made using dissection scissors. The two lateral 
lobes and medial lobe of the mouse liver were gently pulled and exposed out of the 
abdomen. A surgical suture was then threaded around each lobe and tightly secured to 
constrict the blood vessels, at a level in which approximately 60-70% of each individual 
liver lobe volume was distal to the ligation site. Subsequently, the lobes were removed 
with a sharp surgical blade at the level of the ligation; the tightness of the ligation itself 
precluded post-excisional abdominal bleeding. 2´ 104 to 2´ 105 GFP+ cells in 20-30ml PBS 
were then injected slowly using a 0.5ml insulin-syringe into the spleen along the spleen 
longitudinal axis. The incision in the body wall was sutured and the skin was closed with 
wound clips. In sham-transplanted mice, 20-30ml PBS was injected in place of cells. For 
cell transplantation in Hp- and ApoE- deficient mice, 15mg/kg bw of the 
immunosuppressive drug, ciclosporin (Novartis, Switzerland; http://www.novartis.com) 
was intraperitoneally injected daily. 
2.5 Collection of tissues  
Mice were anesthetized and perfused with 10ml saline via the left cardiac 
ventricle followed by either 30-40ml cold 0.5 % (w/v) glutaraldehyde (Sigma; St Louis, 
MO) in PBS for b-gal analysis, or cold 4 % (w/v) paraformaldehyde (Sigma; St Louis, 
MO) in PBS for immunohistochemical staining. Blood samples were collected retro-
orbitally before perfusion with heparinized capillary tubes and centrifuged at 2,000g for 
10min. The sera were transferred to microfuge tubes, and stored at 4ºC. Hp-deficient mice 
were treated with LPS 0.1mg/10g bw 24 hours prior to being sacrificed. 
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2.6 b -gal assay – X-gal staining  
To analyze liver cells for the presence of b-gal, liver samples were cryosectioned 
at 12mm thick (Leica CM3050), and the sections were placed in a 12-well tissue culture 
dish filled with PBS. After washing with PBS, sections were soaked in X-gal staining 
solution [10mM PBS, 2mM MgCl2, 0.01% sodium deoxycholate, 0.02% NP-40/IGEPAL, 
5mMK3Fe(CN)6, 5mMK4Fe(CN)6, 0.1% X-gal (Sigma; St Louis, MO)] (Mercer, Hoyle et 
al. 1991) and incubated at 37ºC for 2-3 hours with gently shaking. Then sections were 
washed three times with PBS, mounted on slides, photographed before counterstaining 
with hematoxylin and eosin (H&E). 
2.7 Immunohistochemistry (IHC) 
Immunohistochemistry (IHC) is a microscopic method whereby antigens can be 
identified within the specimen and their localization compared to the architecture of the 
specimen. IHC thus deals with the structure and function of all molecules of 
immunological importance. The basic principle of IHC is the use of enzyme-linked 
antibodies to detect tissue antigens. The colorless substrate is converted by the enzyme 
into a colored product that precipitates on the slide at the site of the reaction. Thus, IHC 
localizes antigens in a tissue section. 
5mm thick cryosections were mounted onto polylysine-coated slides. Endogenous 
peroxidase of tissues was quenched in 3% H2O2 (1 vol 30%H2O2 plus 9 vol methanol) at 
4ºC for 30 min. After washing in PBS, sections were incubated for 1 hour in blocking 
solution [5% rabbit serum (DAKO, Denmark), or swine serum (DAKO, Denmark) in 
0.3% Triton X-100 PBS for ApoE, or for albumin, respectively]. Then sections were 
primed with either goat anti-mouse ApoE antibody (1:100 dilution in 2% rabbit serum) 
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(Chemicon International Inc, Temecula, CA) or rabbit anti-mouse serum albumin (1:100 
dilute in 2% swine serum) (Accurate Chemical and Scientific Corp, Westbury, NY) for 2 
hours, followed by biotin-conjugated rabbit anti-goat antibody (1:400 dilution in PBS) 
(DAKO, Denmark, http://www.dako.com) or biotin-conjugated swine anti-rabbit 
antibody (1:400 dilution in PBS) (DAKO, Denmark), respectively for 30min. Subsequent 
to 30min incubation with streptavidin-HRP (1:500 dilution in PBS) (DAKO, Denmark), 
sections were stained with DAB chromogen (Sigma, St Louis, MO) for 7-10min and then 
counterstained with Mayer's hematoxylin. The sections were performed with dehydration 
procedure for light microscopy observation.  
2.8 DNA and RNA extractions and Reverse Transcriptase-Polymerase Chain 
Reaction (RT-PCR) analyses 
DNA extraction 
Liver tissues were digested in lysis buffer (50mM Tris-HCl pH7.0, 100mM NaCl, 
500mM EDTA, 1% SDS, 5mM dithiotheritol (DTT), 0.5mM spermidine; 1mg/ml 
proteinase K) at 55ºC overnight with shaking. The digested tissues were extracted with 
equal volume of tris-buffered phenol (pH8.0) for 5-10min and centrifuged at 12,000rpm 
for 3min. The supernatants were transferred to new tubes, and extracted with equal 
volume of [1 vol phenol:1vol CIA (24 vol chloroform: 1 vol Isoamyl alcohol)] followed 
by equal volume of CIA. Genomic DNA was precipitated by addition of 2 vol of ethanol, 
washed twice with 70% ethanol and then dissolved in water. 
Pure RNA extraction 
For preparation of RNA, livers were snap-frozen in liquid nitrogen and stored at 
-80ºC until use.  Frozen liver samples were homogenized (at room temperature) in 1ml of 
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GITC buffer (4M guanidinium thiocyanate, 25mM sodium citrate, pH7.0; 0.5% N-lauroyl 
sarcosine, 0.1M 2-mercaptoethanol) acidified with sodium acetate (0.1ml 2M sodium 
acetate pH4.0 per ml of GITC buffer). The homogenate was incubated at 4°C for at least 
1 hour. The sample was gently overlaid on 2.5ml of CsCl (5.7M CsCl 0.01M EDTA) in a 
polyallomer ultracentrifuge tube, and then centrifuged at 48,000rpm, 20°C for 18 hours 
(SW55 TI rotor; L-80 ultracentrifuge, Beckman, Ireland). The proteinaceous and DNA 
bands were gently removed; the RNA pellet was dissolved in 300ml of diethyl 
pryrocarbonate (DEPC)-treated water. RNA was precipitated by addition of 0.1vol of 3M 
sodium acetate pH5.5 (30ml) and 2vol of ethanol (600ml), and incubated at -20°C for 1 
hour. Centrifugation was done at 14,000rpm at 4°C for 15min. RNA pellet was washed 
with DEPC-treated 70% ethanol. The pellet was dissolved in 50-70ml DEPC-treated water 
and stored at -20°C. 
Crude RNA extraction 
The cell pellets were resuspended in lysis buffer (106 cells/ml) (1ml GITC buffer, 
0.1ml 2M sodium acetate pH4.0, 1ml water-saturated phenol). Cells were immediately 
lysed by passing the cells through a 25G needle several times with a syringe. Then cell 
lysate solution was incubated on ice for at least 15min. 0.25ml CIA was then added to the 
lysate and mixed vigorously. Samples were centrifuged at 10,000g for 3min. The aqueous 
phase with RNA was transferred to a fresh tube, and extracted with equal volume of 1:1 
phenol/CIA followed by equal volume of CIA. RNA was precipitated with 2 vol ethanol 
at -20ºC for at least 2 hours. After centrifugation for 10min at 4ºC, the RNA pellet was 
washed in DEPC-treated 70% ethanol, and then dissolved in 20ml DEPC -treated water.  
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RT-PCR analysis 
H Ghobind Khorana and his colleagues first proposed the method, PCR, in early 
1970s as a strategy to lessen the labor involved in chemical synthesis of genes. This 
technique was independently conceived 15 years later, given its present name, and put 
into practice by Kary Mullis and coworkers at Cetus Corporation, who described in vitro 
amplification of Single-copy mammalian genes using the Klenow fragment of 
Escherichia coli DNA polymerase I. By the end of 1980s, PCR had become a 
fundamental cornerstone of genetic and molecular analyses. The principles of PCR for 
extensive synthesis of the duplexed genes are the following. The DNA duplex would be 
enatured to form single strands. This denaturation step would be carried out in the 
presence of a sufficiently large excess of the two appropriate primers. Upon cooling, one 
would hope to obtain two structures, each containing the full length of the template stand 
appropriately complexed with the primer. DNA polymerase will be added to complete the 
process of repair replication. Two moleculaes of the original duplex should result. The 
whole cycle could be repeated. Simply, PCR is an iterative process, consisting of three 
elements: denaturation of the template by heat, annealing of the oligonucleotide primers 
to the single-stranded target sequences(s), and extension of the annealed primers by a 
thermostable DNA polymerase (http://www.MolecularCloning.com). RT-PCR is a 
method used to amplify cDNA copies of RNA. The underlying concepts are following: 
the first step is the enzymatic conversion of RNA into a single-stranded cDNA templete; 
an olilgodeoxynucleotide primer is hybridized to the mRNA and is then extended by an 
RNA-dependent DNA polymerase to create a cDNA copy that can be amplified by PCR 
(http://www.MolecularCloning.com).  
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RNA and DNA were quantitated using, respectively, the RiboGreen RNA 
Quantitation kit and the PicoGreen dsDNA Quantitation kit (Molecular Probes, Eugene, 
Oregon). RT-PCR was performed as previously described, and cDNA was synthesized 
from 2mg total RNA with oligo (dT) (Lim, Kim et al. 1998). PCR was performed by using 
Taq DNA polymerase (http://www.promega.com) (94°C 30 second, 60°C 30 second and 
72°C 1 min, 35 cycles). Each mRNA, the size (bp) of the amplified PCR product and the 
RT-PCR primers are: (i) AFP mRNA (471 bp) 5’-TCC ACG TTA GAT TCC TCC CAG-
3’ and 5’-TTG CAG CAT GCC AGA ACG ACC-3’, (ii) albumin mRNA (866 bp) 5’-
TTGCTG CTG ATT TTG TTG AGG-3’ and 5’-GAG AAG GTT GTG GTT GTG ATG-
3’, (iii) triose phosphate isomerase (TPI) mRNA (523 bp) 5’-CCC TGG CAT GAT CAA 
AGA CTT-3’ and 5’-GAT GGG CAG TGC TCA TTG TTT-3’, (iv) haptoglobin mRNA 
(895 bp) 5’-AAA CGA CGA GAA GCA ATG GGT-3’ and 5’-GAA GGC AGG CAG 
ATA GGC ATG-3’, (v)  ApoE mRNA (451 bp) 5’-CTG AAC CGATTC TGG GAT 
TAC-3’ and 5’-GCT CAC GGA TGG CAC TCA CAC-3’. All RT-PCR primers span at 
least one intron. PCR amplification of genomic DNA for the AFP/GFP hybrid marker 
gene by PCR was performed using conditions similar to those for RT-PCR. The 5’ primer 
is specific for AFP exon 1 (5’-AAA GGA CTT CAG CAG GAC TGC-3’), and the 3’ 
primer is specific for GFP (5’-TCG TCC TTG AAG AAG ATG GTG-3’). The expected 
PCR fragment size is 363 bp. All RT-PCR or PCR primers were designed using genomic 
sequences retrieved from Genbank. 
2.9 Immunoprecipitation 
20ml homogeneous Protein G-Agarose (Roche Molecular Biochemicals, 
Indianapolis, IN) was mixed with 60mg (20ml) goat anti-human haptoglobin (3mg/ml) 
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(Sigma, St Louis, MO) in 60ml of solution 1 (50mM Tris-HCl, 150mM NaCl, pH7.4) to 
give a final reaction volume of 100ml and incubated for at least 3 hours or over night at 
4°C on a shaking platform. The mixture was centrifuged for 20 seconds at 12,000g and 
supernatant was discarded carefully. To immunoprecipitate haptoglobin in the 
transplanted mouse sera, the Protein G-Agarose pellet was resuspended in 100ml mouse 
serum and 100ml solution 1 and incubated at 4°C on a shaking platform for 1 hour. The 
suspension was centrifuged at 12,000g for 20 seconds. After discarding the supernatant, 
the pellet was washed in 1ml solution 2 (50mM Tris-HCl, 150mM NaCl, 0.5% (w/v) 
sodium deoxycholate, pH7.4) for 20min at 4°C in shaking platform before centrifuging at 
12,000g for 20 seconds. The wash was repeated once more. The pellet was further 
washed in 1ml solution 3 (50mM Tris-HCl, 0.5% (w/v) sodium deoxycholate) twice. 
2.10 Western blot analysis 
. In Western blot analysis, proteins will be denatured into its constituent subunits 
in the presence of sodium dodecyl sulfate (SDS) and dithiotheritol (DTT). These reduced 
and denatured proteins are first seprarated in a gel according to molecular weight ratio. 
The separated proteins are transferred quantitiatively and irreversibly to nitrocellulose or 
nylon membrane by electroblotting. Transferring the proteins to a membrane makes the 
proteins accessible to antibody binding. Proteins of interest are identified by using 
antibody specific for the protein. 
For western blot analysis, the immunoprecipitated pellet or 1ml of mouse serum 
was mixed in 15ml sample loading buffer [9.5ml H2O, 5ml 3× Loading buffer (1M NaCl, 
3mM EDTA, 6% SDS, 0.03% Bromophenol blue, 30% glycerol), 0.5ml 1.25M DTT], 
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denatured at 95°C for 3min, and then loaded on 10% SDS-polyacrylamide gel (BioRad 
Acrylamide, Herculese, CA). For immunoprecipitated pellet, the mixture was centrifuged 
for 20 seconds at 12,000g, and supernatant was loaded on gel. The samples were 
separated at 15mA current for 3-4 hours in 1×Electrophoresis Buffer (5× Electrophoresis 
Buffer: 15.1g/liter Tris base, 72g/liter glycine, 5g/liter SDS) with mini-gel apparatus 
(Mini-ProteanÒ II, BioRad Laboratories, Hercules, CA). After separation, the gel and a 
prewetted nitrocellulose membrane (Schleicher & Schuell, Germany) were equilibrated in 
transferring buffer (40ml 5× Electrophoresis Buffer, 60ml methanol, 200ml H2O) for 
30min. The separated proteins in the gel were transferred to the nitrocellulose membrane 
by electroblotting (Trans-Blot SD, BioRad Laboratories, Hercules, CA) at a constant 15V 
for 1 hour. The blotted membrane was incubated in blocking buffer (5% skim milk in 
TBS/Tween; TBS: 100mM Tris-HCl, 0.9% NaCl; TBS/Tween: 0.1% Tween20 in TBS) 
with shaking over night at 4°C. For detection of haptoglobin, the membrane was primed 
with goat anti-human haptoglobin (1:1000 dilution in TBS/Tween) followed by HRP-
conjugated rabbit anti-goat antibody (1:5000 dilution in TBS/Tween). For detection of 
ApoE, the membrane was primed with goat anti-mouse ApoE (Santa Cruz Biotech Inc, 
Santa Cruz, CA) (1:100 dilution in TBS/Tween), followed by biotin-conjugated rabbit 
anti-goat (1:5000 dilution) (DAKO, Denmark) and then HRP-conjugated Neutravidin 
(1:10000 dilution) (Pierce, Rockford, IL). Each step required 1 hour of incubation at room 
temperature. The membranes were then incubated with Enhanced Chemiluminescent 
Substrate (ECS) (Pierce, SuperSignal West Pico Chemiluminescent Substrate, Rockford, 
IL) for 5min, and exposed to X-ray film (BioMax film, Eastman Kodak Company, NY).  
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3 Results 
3.1 Modification of ES cells by homologous recombination of GFP gene with AFP 
locus 
 To express GFP under the regulatory control of the AFP locus, the coding region 
of a GFP gene was inserted in-frame with the translation start codon of the AFP locus in 
ES cells (CS1-ES cells) by homologous recombination. The AFP gene has 15 exons and 
the targeting vector was a replacement vector consisting of the GFP gene and a floxed 
(PGK Neo-PGK TK) selectable marker gene flanked by 2 and 5 kb of homologous 
sequences at the 5’ and 3’ ends, respectively (Figure 1B, C). The vector was designed to 
replace AFP coding sequences in exon 1 and 2 with those of GFP gene (Figure  1D). The 
NotI linearized targeting vector was electroporated into ES cells. Targeted ES cell clones 
were selected by G418 treatment and analyzed by Southern blot hybridization using a 
single copy probe, a HindIII/BamHI fragment derived from exon 6 and intron 6 of the 
AFP gene (Figure 1A). The probe detected a 12-kb HindIII fragment from the wildtype 
allele and a 5-kb HindIII fragment from the recombined allele (Figure 2). Approximately 
1% of clones are targeted by homologous combination. 








Figure 1 GFP recombination at the AFP locus. A) A HindIII/BamHI fragment derived 
from exon 6 and intron 6 of the AFP gene was used as probe for southern blot 
hybridization. B) wild-type AFP Locus contains 15 exons. C) Targeting vector for GFP 
knock-in at the AFP locus consists of the GFP gene and a floxed (PGK Neo-PGK TK) 
selectable gene flanked by 2 and 5kb of AFP homologous sequences at the 5’ and 3’ ends. 
The ATG translation start codon of the GFP gene was cloned in-frame with that of the 
AFP gene. The vector was designed to replace AFP coding sequences in exon 1 and exon 
2 with GFP. D) Homologously recombined locus. 
 
Figure 2 Southern blot hybridization of genomic 
DNA from WT and recombinant ES (rES) cell 
clones. The probe detects a 12-kb HindIII WT 
fragment and a 5-kb HindIII recombined fragment. 
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3.2 AFP/GFP expression in in vitro differentiated rES cells 
To investigate temporal and spatial expression of GFP in EBs derived from rES 
cells, rES cells were grown at 106cells/ml in suspension without LIF on Petri dish. Under 
this condition, the cells aggregated to form EBs. After 4 days, EBs were harvested and 
transferred to another Petri dish. At day 5 (D5), D8, and D12 of differentiation, EBs were 
harvested, allowed to adhere to tissue culture slides and viewed under confocal 
microscope. At least 6 EB-derived colonies at each time-point were observed. As shown 
in Figure 3, very few GFP+ cells were detected in undifferentiated rES cells. However, 
when induced to differentiate into EBs, GFP+ cells appeared in a specific temporal and 
spatial distribution. At D5, GFP+ cells were sparsely dispersed in the EBs but by D8, 
there was a dramatic increase in GFP+ cells that nearly covered the whole EBs. However, 
at D12, the GFP+ cells were seen only at the center of EBs. These observations suggested 
that AFP/GFP expression was regulated in differentiating ES cells. 
To study further the GFP expression in differentiated rES cells, a two-step 
differentiation protocol (Wiles 1993) was used to differentiate rES cell in order to 
produce better sychronized EBs. Single rES cells were plated in methycellulose-based 
differentiation medium. Six days later, the rES cells formed primary EBs that were 
uniformly sized, tightly packed, round and semi-transparent clusters of cells (Figure 4).  
These primary EBs were dissociated into single cells and replated to form secondary EBs 
in methycellulose-based differentiation medium with or without addition of Hepa-
conditioned medium. To investigate GFP expression during differentiation, EBs were 
harvested at different times and dissociated into single cells for FACS analysis for the 
presence of GFP+ cells. The number of GFP+ cells in undifferentiated ES (Day 0) cells 
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and D6 primary EBs were not significantly different and constituted <10% (Figure 5). 
The yield of GFP+ cells peaked in D3 of secondary EBs with about 80% of the cells being 
GFP+ and remained relatively stable in D6, 9, and 12 of secondary EBs. Therefore, 
AFP/GFP expression was initiated in Day3 of second EBs and continued throughout the 
development of EBs up to Day12 of secondary EBs. As verification of the FACS 
analysis, GFP+ cells were visible in the D6 of second EBs and not in the undifferentiated 
rES cells (Figure 6). The expression difference of GFP positive cells in Figure 6 and in 
Figure 5 could be due to the sensitivity of different instrument used. Noisy signal may 
exist in the FACS analysis. Since low percentage of green fluorescent signal was detected 
on D0 of undifferentiated rES cells. Furthermore, AFP mRNA was detectable in GFP+ 
cells, but not in undifferentiated rES cells, primary EBs, GFP- cells, and D6 secondary 
EBs (Figure 7). This result indicates that AFP gene co-expresses when GFP gene 
expresses. Meanwhile, GFP+ cells also express albumin mRNA which is representative of 
early fetal hepatocytes (Sellem, Frain et al. 1984; Schmid and Schulz 1990). The 
experiment was repeated twice. 
To determine if Hepa-conditioned medium would improve the viability and yield 
of AFP/GFP+ cells, medium for growing secondary EBs were supplemented with Hepa-
conditioned medium. On D6, we observed a small but consistent increase of 10% in cell 
viability but not in the yield of GFP+ cells as compared to secondary EBs grown without 
Hepa-conditioned medium  (Table 1).  
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Figure 4 rES-derived EBs at day 6. Singly dispersed rES cells at exponential 
growth were suspended in Methycellulose-based medium. 6 days after plating, 





Figure 3 Fluorescent microscopy of GFP expression in EBs during in vitro 
differentiation using suspension culture method (Robertson EJ 1987). rES cells were 
individually resuspended at 106 cells/ml to form EBs. After 4 days, EBs were transferred 
to a bacteriological Petri dish. At 5 days (D5), D8 and D12, EBs were harvested and 
allowed to adhere to tissue culture slide before viewing. Confocal microscopic result 
shows that the GFP expression was sparce at D0 and D5 differentiation. However, there 
is a high expression at D8 rES formed EB. The figure demonstrated an increase and 
decrease, and different spatial distribution of green fluorescence. Amplification 10´20 
ES colony 5 days 
8 days 12 days 
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Figure 5 FACS analyses of AFP/GFP rES cells by using a two-step in vitro differentiation 
method (Wiles MV 1993). X axis represents GFP; Y axis cell size . rES cells were 
dispersed individually in methycellulose-based media (first differentiation). After 6 days, 
the formed EBs were harvested and collagenase digested into single cells. These first-
differentiated cells were replated back to same media with or without addition of Hepa-
conditioned medium (second differentiation). In figure, Day9, Day12, Day15 or Day18 
represent Day3, Day6 or Day9 of second EBs, respectively. Day6-EBs or the following 
dispersed cells were harvested at different time intervals during differentiation. By 
undifferentiated recombinant ES cells as a negative control, AFP/GFP expression profile 
    
Undifferentiated ES cells
  
Differentiated ES cells on Day12
 
 
Figure 6 Fluorescent microscope results in undifferentiated and differentiated ES 
cells. It shows that there were no GFP+ cells in undifferentiated ES cells, but 
some of GFP+ cells (green fluorescent color) were shown on Day 12 after 
differentiation. Amplification 10´40 
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Figure 7 RT-PCR pictures demonstrate the mRNA expressions of AFP and 
Albumin in recombinant ES cells, Day 6 EBs, Day 12 differentiated recombinant 
ES cells, GFP- and GFP+ cells after FACS sorting. The sorted GFP positive cells 







Average yield (n=3) 31±3% 35±9% 
Viability (n=3) 62±6% 77±6% 
 
Table 1 Table shows the yield and viability of whole cell population and GFP positive 
cells in in vitro differentiation medium with or without hepa-condition media. The 
average yield and viability were represented by cell number±SEM%. 
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3.3 Engraftment and differentiation of GFP+ cells to hepatocyte-like cells  
To determine if the AFP/GFP+ cells were liver progenitor cells that can engraft 
and differentiate into hepatocytes in vivo, we transplanted these cells into lacZ-positive 
F1 (B6.129S7-Gtrosa26×129/Sv) hybrid mice. B6.129S7-Gtrosa26 is a transgenic mouse 
line that expresses E.coli lacZ in all tissues and the parental ES cell line, CS-ES was 
derived from the129/Sv strain of mice. Since the transplantation experiment with 
allogeneic haematopoietic stem cells (HSCs) from parent demonstrated that HSCs could 
engraft and across histocompatibility barrier (Shizuru, Jerabek et al. 1996).  Another is 
that a mouse F1 model of transplantation tolerance in radiation chimaeras can be 
generated by prior to reconstitution with parental fetal or neonatal liver cells (Umiel 
1975). Both results suggest that stem cells or progenitor cells, probably like ES cell-
derived progenitor cells, could overcome certain level of histocompatibility. When 
transplanted into F1 (B6.129S7-Gtrosa26×129/Sv) mice, CS-ES cell-derived cells could 
not or could be slightly rejected. rES cell-derived hepatocyte-like cells can be easily 
distinguished from the lacZ-positive host hepatocytes by its absence of b-gal with X-gal 
staining. Figure 8 demonstrated that the Rosa26 mouse liver was stained as blue after X-
gal staining in comparison with wild type mouse liver. 
Before transplantation of the GFP+ cells, rES cells were tested for pluripotency by 
evaluating its ability to form teratoma. When undifferentiated rES cells were 
intrasplenically injected into PHx LacZ-positive F1 hybrid mice, teratomas were observed 
in the livers of all transplanted mice (n=4) but no teratoma was observed when the cells 
were injected into LacZ-positive F1 hybrid mice without hepatectomy (n=4) (data not 
shown). The teratomas were all rES cell-derived as evidenced by the lack of b-gal after 
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using X-gal substrate to staining the sections (Figure  9). The rES cell-derived teratoma 
contains various types of tissues such as cartilage, bone, muscle, squamous and glandular 
epithelia indicating that the rES cell remained pluripotent even after genetic manipulation.  
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Figure 8 The Rosa26 mouse liver (a transgenic mouse) and 129sv mouse liver (a 
wild type mouse) were removed, fixed and stained with X-gal. The whole liver was 
blue in Rosa26 mouse liver (lower), but not wild type mouse liver (upper). 
Figure 9 X-gal and H&E staining showed the teratoma formed by injection of rES 
cells into PH´ mice. Different cell types, such as muscle, cartilage, bone, squamous 
and epithelial cells, etc, were demonstrated in the teratoma. Amplification 10´5 for 
left panel, 10´20 for right panel   
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  PHx hybrid F1 mice were injected intrasplenically with 2´ 103 - 2´105 GFP+ cells, 
which were sorted by FACS on D6 of secondary EBs. Three weeks later, liver samples 
were harvested and X-gal staining stained cryosections for the presence of b-gal. To 
ensure complete staining, these sections were always stained in the same dish with liver 
sections from sham-transplanted mice. As expected, every cell in the liver sections from 
the sham-transplanted animals was b-gal+ as evident by the blue staining (Figure 10). In 
the transplanted animals, AFP/GFP+ cell-derived cells were evident as clusters of b-gal- 
cells as opposed to the b-gal+ host cells in the liver sections. These cells were about 15-20 
mm in diameter and were integrated into the architecture of the recipient liver, forming 
continuous hepatic cords with recipient liver cells (Figure 10). Varying numbers of rES 
cell-derived AFP/GFP+ cells (2´103 - 2´105 cells per mouse) had been transplanted into 
PHx mice. Unlike undifferentiated rES cells, no teratoma was observed in any AFP/GFP+ 
cell transplanted mice (n>100), and experiments were duplicated at least twice. The 
engraftment of AFP/GFP+ cells into the recipient livers was further confirmed by the 
presence of AFP/GFP hybrid gene in transplanted mouse livers and not in the control 
mouse livers (Figure 11). 
To determine if transplanted AFP/GFP+ cells had differentiated into hepatocyte-
like cells, liver sections from AFP/GFP+ cell transplanted liver samples that were stained 
with X-gal were counterstained for the presence of albumin and ApoE by 
immunohistochemical staining. Consistent with the earlier observations, b-gal- cells were 
positive for albumin and ApoE (Figure 12) indicating that the engrafted AFP/GFP+ cells 
had differentiated into albumin and ApoE producing hepatocyte-like cells in vivo. To 
further verify the hepatic functionality of the engrafted AFP/GFP+ cells, the AFP/GFP+ 
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cells were transplanted into PHx ApoE- or Hp- deficient mice (n>30 each group). Three 
weeks after transplantation, ApoE and haptoglobin mRNAs were detected by RT-PCR 
analysis to be present in the livers of ApoE- or Hp- deficient mice, respectively (Figure 
13). Consistent with this, immunohistochemical analysis also demonstrated the 
incorporations of clusters of 2-5 ApoE+ hepatocyte-like cells into the hepatic cords of the 
transplanted ApoE-deficient mice (Figure 14). Western analysis also confirmed that the 
presence of ApoE (Figure 15) or haptoglobin (Figure 16) in the sera of transplanted 
ApoE- or Hp- deficient mice, respectively. Taken together, these results suggested that 
AFP/GFP+ cells derived from rES cell engrafted in the recipient liver, differentiated into 
functional hepatocytes by producing liver specific proteins of albumin, ApoE and 
haptoglobin. 
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Figure 10 Pictures showed the X-gal staining of liver sections from GFP+ cell 
transplanted Rosa26 mice that ubiquitously express beta-galactosidase in all tissue 
(X-gal staining positive). rES cell (GFP+ cell)-derived cells (in frame) were X-gal 
negative (non-blue cells) in the host blue background. Morphologically, these non-
blue cells are similar to hepatocytes. They integrated into hepatic cord by individual 
cells or a group of cells. Amplification 10´20 
Figure 11 PCR result showed that AFP/GFP hybrid gene could be detected in 
recipient mouse livers after transplantation of GFP+ cells. Genomic DNA was 
extracted from rES-derived AFP/GFP+ cell transplanted mouse liver samples.  
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Figure 12 Immunohistochemical staining showed that albumin and ApoE expressions could 
be demonstrated in X-gal negative cells that should be derived from transplanted AFP/GFP+ 
cells after X-gal staining in the same section. X-gal negative Cells with brown color are 









Figure 13 RT-PCR analysis demonstrated the presence of ApoE or haptoglobin 
mRNA in ApoE- or Hp-deficent mice after GFP+ cell transplantation. In each 
sample, 2ml and 0.2ml volumes of original RT solution were used in following 
PCR. TPI acts as an internal control. 
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Figure 14 Immunohistochemical staining 
demonstrated the presence of ApoE in 
ApoE-deficent mice after GFP+ cell 
transplantation. A group of ApoE positive 
cells were shown and integrated into the 
hepatic plate morphologically (rectangular 
frame). Amplification 10´40 
Figure 16 Immunoprecipitation and 
Western-blot analyses showed 
haptoglobin protein in Hp-deficient 
mouse with LPS treatment after GFP+ 
cell transplantation. 
            AFP/GFP+ Transplanted ApoE-/- Mice                          
ApoE-/-  ApoE+/+      mouse 1     mouse 2   mouse 3   mouse 4    mouse 5  
 
 
Figure 15 Western-blot showed ApoE protein in ApoE-deficient mouse after AFP/GFP+ cell 
transplantation. ApoE protein was detectable in five transplanted ApoE-deficient mice after 
transplantation of rES cell-derived GFP cells.  
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4 Discussion 
The ability of ES cells to develop into all cell types including germ cells has made 
it a versatile research tool and potential therapeutic reagent. With the recent isolation of 
human ES cells from embryonic tissues and the generation of ES cells from individual 
adult tissues by nuclear transplantation, the use of ES cells as potential therapeutic 
reagents has become a lot more realistic (Wilmut, Schnieke et al. 1997; Shamblott, 
Axelman et al. 1998; Thomson, Itskovitz-Eldor et al. 1998; Wakayama, Perry et al. 1998; 
Reubinoff, Pera et al. 2000). As a result, ES cell technology may form the basis of new 
gene therapy and cell replacement in disease tissue. 
Currently, there is much interest in the generation of tissue-specific cell type from 
ES cells as an alternative source of cell transplantation. An approach in development of 
cell replacement therapy is to use a tissue-specific promoter to drive a selectable marker 
or a foreign gene to select certain population of ES cell derivatives (Klug, Soonpaa et al. 
1996; Li, Pevny et al. 1998), which was also used in our experimental process, but a 
major concern is the potential malignancy of genetically manipulated cells. We 
hypothesized that using committed tissue-specific stem/progenitor cells from 
differentiated ES cells may eliminate the tumorigenic potential, and produced the 
appropriate tissue. Consistent with this hypothesis, our data showed that all mice 
transplanted with ES cells developed teratomas, but none of mice transplanted with 
differentiated ES cells developed teratomas. The maximal number of AFP/GFP cells that 
were transplanted in the experiments were 2´105 cells per mouse. It is 5 times less 
compared to 106 undifferentiated rES cells per mouse for teratoma formation. Therefore, 
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inconclusively, our data suggest that sufficiently differentiated ES cells may not form ES 
cell-derived teratoma in in vivo transplantation. 
Although several reports have described the derivation of hepatic cells from ES 
cells (Hamazaki, Iiboshi et al. 2001; Chinzei, Tanaka et al. 2002; Yamada, Yoshikawa et 
al. 2002), it is critical to determine if these ES cell-derived hepatic cells function in a 
normal physiological way. AFP is one of the earliest proteins expressed in the hepatic 
lineage during embryonic development (Dziadek and Andrews 1983; Sellem, Frain et al. 
1984). Moreover our in vitro studies demonstrated the consistent results with other 
reports that AFP is expressed in differentiated ES cells under temporal and spatially 
regulatory control (Doetschman, Eistetter et al. 1985; Abe, Niwa et al. 1996; Morrisey, 
Tang et al. 1998; Hamazaki, Iiboshi et al. 2001; Chinzei, Tanaka et al. 2002; Jones, Tosh 
et al. 2002). These data suggest that expression of AFP in differentiated rES cells 
supports, but does not prove the existence of hepatic progenitor cells and/or hepatocytes 
in differentiated ES, because these markers are also expressed in visceral endoderm 
(Dziadek and Andrews 1983; Sellem, Frain et al. 1984; Morrisey, Tang et al. 1998). Are 
precursor cells generated outside the context of a multicellular organism sufficiently 
responsive to positional cues to participate in the development and histogenesis of a 
living host? In vivo reconstitution would be a more rigorous test of the potential of ES 
cells to acquire lineage-specific fates. Therefore, transplantation of these AFP/GFP 
expressing cells into recipient mice will strictly confirm if these ES cell-derived cells 
could be progenitors and can give rise to hepatocytes in recipient mice. Our results 
showed that ES cell-derived AFP/GFP expressing cells can be built-in into the host liver 
architecture and differentiate into cells in recipient livers with expression of albumin, 
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ApoE and haptoglobin. Since adult hepatocytes synthesize albumin (Sellem, Gal et al. 
1984), and mainly ApoE (Shore and Shore 1973) and haptoglobin (Lim, Ferraro et al. 
2001). Taken these results together, it suggested that, using AFP as a marker, a certain 
population of cells could be isolated from in vitro differentiated ES cells, and after 
transplantation, these ES cell-derived cell practically functioned as ApoE- and 
haptoglobin-producing cells in vivo in liver-function deficient mouse models, which 
represent some hepatocyte identities. Our data suggest that ES cells can differentiate into 
AFP expressing cells, and furthermore these AFP expressing cells might differentiate into 
hepatocye-like cells after transplantation into PH´ mice. Extensive in vivo and in vitro 
experiments should be carried on to further confirm that these ES cell-derived hepatocyte-
like cells are true hepatocytes.  
In our experiment, the levels of haptoglobin and ApoE detected in ES-derived 
AFP/GFP+ cell transplanted animals were not robust, especially in transplanted 
haptoglobin-deficient mice. One possible explanation for this weak signal may be that 
insufficient number of AFP/GFP+ cells (2´103 to 2´ 104cells per mouse) was transplanted 
into Hp-deficient mice. Another possible explanation may be that not all ES cell-derived 
AFP expressing cells are hepatic lineage (Jones, Tosh et al. 2002) or have liver-specific 
characteristics (Yamada, Yoshikawa et al. 2002). Thirdly, the engraftment efficiency of 
transplanted AFP/GFP expressing cells could be variable, because the AFP/GFP+ cells 
were infused indirectly from spleen (Weglarz, Degen et al. 2000). Therefore, further 
experimental manipulation is needed to improve the extent of repopulation in the liver by 
transplanted AFP expressing cells. Moreover, several important issues will have to be 
addressed before practical applications can be considered. For instance, it remains to be 
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determined if AFP/GFP+ cells are capable of homing specifically to the liver. The 
consequences of AFP/GFP+ cell engraftment into nonhepatic tissues will also have to be 
determined. The AFP-modified ES cells are not adequately equipped to resolve these 
issues because GFP expression in the ES cells is driven by AFP expression, and any 
further differentiation of AFP cells would invariably shut down the expression of GFP if 
AFP expression were off. Therefore, the use of a second specific marker will be necessary 
for assessing the homing specificity of the transplanted cells. It is possible that y 
chromosome detection by fluorescence in situ hybridization will not be an adequate 
marker for tracking the small number of transplanted cells.  
During in vitro differentiation of rES cells to AFP/GFP+ cells, increasingly 
lineage-restricted stem cells are generated. It is likely that the progenitor cells preceding 
AFP/GFP expressing cells are also capable of differentiating into hepatocyte-like cells in 
vivo. With the differentiation of ES cell-derived AFP+ cells up to the stage of Albumin 
production, hepatic lineage differentiation is not distinguishable from yolk sac lineage 
differentiation. Consistent with this hypothesis, GFP- cells from the first and second step 
of ES cell differentiation also gave rise to ß-gal- hepatocyte-like cells in ß-gal+ recipient 
background (data not shown). This observation suggested the presence of at least a more 
primitive progenitor cell than the AFP/GFP expressing cells. As the first type of cells to 
be purified from differentiated ES cells, the AFP/GFP+ cells will provide a good reference 
for the identification of more primitive progenitor cells for differentiation into 
hepatocyte-like cells in liver. Combinatorial approaches using multiple promoters and 
selectable markers also can be envisioned. While the selection procedure described here 
does not provide a source of continuously proliferating cells, the parental ES cells can be 
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maintained and expanded infinitively in an undifferentiated state. It is possible to generate 
virtually unlimited numbers of AFP/GFP+ cells ex vivo and/or genetically modified donor 
cells from ES cells for transplantation. 
Generation and identification of human ES cells and EG cells (Shamblott, 
Axelman et al. 1998; Thomson, Itskovitz-Eldor et al. 1998), and generation of ES cells 
from mature tissue by reprogramming (Wilmut, Schnieke et al. 1997; Wakayama, Perry 
et al. 1998) extend the potential use of ES cells. Furthermore, human ES cells can 
reproducibly differentiate in vitro into EBs comprising the three embryonic germ layers 
including cells of neuronal, hematopoietic and cardiac origins (Itskovitz-Eldor, 
Schuldiner et al. 2000; Schuldiner, Yanuka et al. 2000). Therefore, it is potentially a 
source of differentiated cells for cell replacement therapies for the treatment of many 
diseases including liver transplant therapy. 
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Part II Derivation of Hepatocyte-like cells from BM cells 
without Hematopoietic Reconstitution 
Abstract 
Generation of hepatocytes from donor bone marrow (BM) cells has been 
demonstrated in animal models and patients with hematopoietic reconstitution. However, 
hematopoietic reconstitution is a highly risky procedure that will severely limit any 
potential clinical applications of hepatic replacement by BM cell. We show here that 
intrasplenic transplant of BM mononuclear cells into partially hepatectomised (PHx) 
recipient mice did not result in any detectable BM-derived hepatocyte but was apparent 
only as BM-derived non-parenchymal cells (NPCs). However, after transplantation of 
these NPCs into anther PHx mice, BM-derived hepatocyte-like cell was detectable, but 
rare. When BM cells from FasLPR mice were transplanted into PHx ApoE-deficient mice 
followed by six weekly sub-lethal injections of anti-Fas antibody to induce chronic 
hepatic deficiency, BM-derived ApoE+ hepatocyte-like cells and serum ApoE were 
detectable in the transplanted animals. Our study demonstrated that hematopoietic 
reconstitution is not necessary in derivation of hepatocyte-like cells from BM cells. 
Moreover the frequency of BM-derived hepatocyte-like cell is rare and is dependent on 
having a sufficiently lengthy period of liver regenerative microenvironment. 
Nevertheless, this rare event can still be exploited for therapeutic applications by 
providing the BM-derived hepatocytes with a selective survival advantage over host 
hepatocytes. 
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1 Introduction 
1.1 General Statement 
Stem cells are known to exist in adult tissues, such as central nervous system, 
epidermis, intestine, bone marrow (BM), liver and pancreas. It is generally believed that 
stem cells in adult tissues are lineage-restricted and can generate only the types of cells 
present in the tissues where they reside. Adult hematopoietic stem cells (HSCs) in the 
adult BM are the best characterized adult stem cells and they generate all blood cell types 
(Domen and Weissman 1999). BM stroma has also been shown to have mesenchymal 
stem cells (MSCs) that generate osteoblast, chondroblasts, adipocytes, fibrous connective 
tissue, and the reticular network that supports blood cell formation (Owen 1988; 
Pittenger, Mackay et al. 1999). Recently, a series of experiments demonstrated that BM 
might have stem cells that have the potential to differentiate not only into blood cells, but 
also into multiple other cell types in the heart, liver, kidney, lungs, gastrointestinal (GI) 
tract, skin, muscle, endothelium, and even brain. If true, BM will have wide ranging 
therapeutic applications.  
1.2 Non-hematopoietic cell derivatives from BM cells 
In adult, self-renewal, growth and repair of skeletal muscle fibers are sustained 
mainly by differentiation and proliferation of mononucleated myogenic precursors or 
satellite cells (Blau, Dhawan et al. 1993). Recently, several studies indicated that BM 
cells can differentiate into skeletal muscle cells in mouse model of injured skeletal muscle 
and a mdx mouse model of Duchenne muscular dystrophy (Ferrari, Cusella-De Angelis et 
al. 1998; Bittner, Schofer et al. 1999; Gussoni, Soneoka et al. 1999; LaBarge and Blau 
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2002). Furthermore, BM cells can give rise to cardiomyocytes in the mdx mouse model of 
Duchenne muscular dystrophy (Bittner, Schofer et al. 1999), or in a mouse model of acute 
myocardial ischemia (Orlic, Kajstura et al. 2001; Orlic, Kajstura et al. 2001). 
Mobilization of BM stem cells into peripheral blood by stem cell factor (SCF) and 
granulocyte colony-stimulating factor (G-CSF) has also been shown to promote BM cell-
mediated repair of the ischemic tissues (Orlic, Kajstura et al. 2001). These studies suggest 
that transplantation or mobilization of BM stem cells is a potential therapeutic option to 
replace dying muscle cells in muscular dystrophy and myocardial infarction. 
BM also has endothelial progenitor cells, which play a major role in the regulation 
of several postnatal processes. They can be recruited from the marrow and contribute to 
neo-angiogenesis during wound healing, vascularization in post-myocardial ischemia, 
limb ischemia, endothelialization of vascular grafts, arteriosclerosis and retinal 
neovascularization (Rabbany, Heissig et al. 2003). It suggests that they might be essential 
for tissue vascularization and organ regeneration. 
 
In addition to mesodermal myocytes and endothelial progenitor cells from BM 
cells, it has been shown that transplanted BM cells can differentiate into cells expressing 
neural specific markers such as microglial antigenic marker F4/80, astroglial marker 
GFAP or neuronal marker NeuN in the brain (Eglitis and Mezey 1997; Brazelton, Rossi 
et al. 2000; Mezey, Chandross et al. 2000). Recent studies also showed that stromal cells 
from BM can differentiate into cells in vitro with expression of GFAP and NeuN markers 
from mouse and human (Sanchez-Ramos, Song et al. 2000), or of neuron-specific 
enolase, NeuN, neurofilament-M neuronal markers from rat and human (Sanchez-Ramos, 
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Song et al. 2000; Woodbury, Schwarz et al. 2000). These findings raise the possibility 
that BM-derived cells may be used to regenerate neurons in patients with 
neurodegenerative diseases or central nervous system injury.   
 
The possibility of generating endodermal hepatocyte from BM cells was raised 
recently. In 1999, Petersen BE et al. reported the presence of BM-derived male 
hepatocytes after hematopoietic reconstitution of lethally irradiated female rats by male 
BM transplantation followed by hepatotoxic treatment with carbon tetrachloride and 2-
acetylaminofluorene (2-AAF) (Petersen, Bowen et al. 1999). A series of reports 
subsequently confirmed the presence of male hepatocytes in female mice (Theise, Badve 
et al. 2000) and patients (Alison, Poulsom et al. 2000; Theise, Nimmakayalu et al. 2000) 
after hematopoietic reconstitution with male BM, suggesting the derivation of 
hepatocytes from donor BM cells. Some of the strongest experimental evidence that 
demonstrated the derivation of hepatocytes from BM cells were provided by 
transplantation of wild type BM cells into fumarylacetoacetate hydrolase (FAH)-deficient 
mice (Lagasse, Connors et al. 2000) or mouse BM cells expressing human Bcl-2 under 
the control of a liver-specific promoter into wild-type mice with fulminant hepatitis 
induced by Fas antibody (Mallet, Mitchell et al. 2002). In both instances, BM-derived 
hepatocytes were generated in sufficient quantity to successfully rescue or treat the 
transplanted mice.  It was further reported that only HSCs with the potential for long-term 
hematopoietic repopulation can give rise to BM-derived hepatocytes in the FAH-deficient 
mouse (Lagasse, Connors et al. 2000; Krause, Theise et al. 2001). However, BM cells 
such as b-2-microglobulin-negative (b2m-) and Thy-1+ BM cells from rat and human 
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(Avital, Inderbitzin et al. 2001), cells expressing hepatocyte growth factor (HGF) receptor 
(c-Met) and AFP from rat (Miyazaki, Akiyama et al. 2002), and a primitive multipotent 
adult progenitor cells (MAPCs) from human, mouse and rat (Schwartz, Reyes et al. 2002) 
had been shown to give rise to hepatocyte-like cells in vitro  and hepatocytes in 
transplantation experiments (Avital, Feraresso et al. 2002). Together, these studies 
suggest several possibilities: BM contains liver specific stem cells, primitive multipotent 
stem cells, or highly plastic stem cells that can transdifferentiate into liver cells. Despite 
our poor understanding of the overall mechanism in generating hepatocytes from BM 
cells, exploiting this phenomenon of BM-derived hepatocytes for therapy remains highly 
feasible and attractive particularly when current therapeutic options are severely limited 
by donor shortage and immune allograft rejection in orthotopic transplantation. 
One severe limitation of using BM for therapeutic replacement of hepatocytes is 
the low efficiency of generating BM-derived hepatocytes. It was reported that after BM 
transplantation, BM-derived hepatocytes constituted 1-2% of total hepatocytes in mouse 
(Theise, Badve et al. 2000) and human (Theise, Nimmakayalu et al. 2000). Furthermore, 
most documents demonstrated that the level of hepatocytes derived from BM cells is very 
low, approximately 1 in 100,000 host cells (Mallet, Mitchell et al. 2002; Wagers, 
Sherwood et al. 2002; Wang, Montini et al. 2002). However, several groups have shown 
that if BM-derived hepatocytes were given a selective advantage over the host 
hepatocytes, therapeutic levels of BM-derived hepatocytes can be generated. For 
example, transplanting BM cells expressing a liver-specific human Bcl-2 transgene into 
mouse model of fulminant hepatitis resulted in the selective proliferation of the rare 
apoptosis-resistant BM-derived hepatocytes and rescue of the mouse (Mallet, Mitchell et 
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al. 2002). Similarly, when wild type BM cells were transplanted into a FAH-deficient 
mouse model of tyrosinemia, BM-derived hepatocytes with intact FAH alleles survived 
better than the mutant hepatocytes and partially corrected the liver defect (Lagasse, 
Connors et al. 2000). However, in most studies demonstrating the derivation of 
nonhematopoietic cells from BM, such as muscle cells (Gussoni, Soneoka et al. 1999; 
LaBarge and Blau 2002), microglia and astrocytes (Eglitis and Mezey 1997), neuron 
(Brazelton, Rossi et al. 2000; Mezey, Chandross et al. 2000), even liver cells (Petersen, 
Bowen et al. 1999; Lagasse, Connors et al. 2000; Theise, Badve et al. 2000; Krause, 
Theise et al. 2001; Mallet, Mitchell et al. 2002; Wagers, Sherwood et al. 2002; Wang, 
Montini et al. 2002) from mouse or from patients (Alison, Poulsom et al. 2000; Theise, 
Nimmakayalu et al. 2000), ablation of  host hematopoietic system followed reconstitution 
with BM transplantation is an obligate step. In fact, several groups claimed that BM cells 
engraft and differentiate into hepatocytes in mouse models of liver injury only after 
hematopoietic reconstitution but not by direct intravenous injection of BM cells in mouse 
models of liver failure (Mallet, Mitchell et al. 2002; Wang, Montini et al. 2002). These 
data suggest that prior reconstitution of host hematopoietic system is the prerequisite in 
derivation of hepatocytes from BM cells. In contrast, Avital et al have shown that 
intravenous transplantation of b2m-/Thy-1+ rat BM cells can give rise to hepatocytes and 
cholangiocytes in rats transplanted with a mildly mismatched liver (Avital, Feraresso et 
al. 2002). Therefore, it is possible that direct injection of BM cells into recipients with 
liver injury could lead to engraftment and subsequent differentiation into hepatocytes 
without necessitating hematopoietic reconstitution. 
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1.3 The purpose of this study 
The purpose of this study was to determine if direct BM transplantation without prior host 
hematopoietic reconstitution could generate BM-derived hepatocytes. 
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2 Materials and Methods  
2.1 Preparation of mononuclear cells from BM 
Rosa26, C57BL/6J-TgN(MTnLacZ)204Bri (MTnLacZ), ApoE-deficient mice and 
B6.MRL-Tnfrsflpr (FasLPR) (Adachi, Watanabe-Fukunaga et al. 1993) were  purchased 
from Jackson Laboratory (Bar Harbor). C57BL/6J mice were purchased from the 
Laboratory Animal Resource Centre. 
MtnLacZ mouse is a transgenic mouse, and carrys no obvious phenotype. The 
protein product is localized to the cell nucleus. Expression is present in the liver of 
transgenic mice as a result of the presence of the SV40 large T-antigen nuclear 
localization signal peptide. Hepatocytes from this strain stain blue with X-gal staining. 
Expression can be induced up to 10-fold by administration of heavy metal ions 
(http://www.jax.org, (Rhim, Sandgren et al. 1994). 
FasLPR (lymphoproliferation) is a spontaneous mutation mouse. It is caused by 
the insertion of the early transposable element Etn in the Fas gene. The Fas protein is a 
cell surface antigen of about 35kDa that mediates apoptosis. There is a high expression on 
thymic epithelial cells and hepatocytes (Mallet, Mitchell et al. 2002). The Fas protein 
shows structural homology with several cell surface antigen, including the tumor necrosis 
factor (TNF) and the low-affinity nerve growth factor receptor and is considered a 
member of the TNF receptor (TNFR) superfamily.  Fas and its ligand are also involved in 
down-regulating immune reactions. Homozygous mice show systemic autoimmunity, 
massive lymphadenopathy associated with proliferation of aberrant T cells, arthritis, and 
immune complex glomerulonephrosis (http://www.jax.org).  
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Mice were killed by cervical dislocation before removing the femurs. BM cells 
were flushed out of the femurs with cold 2% FBS in PBS. BM cells were dispersed into 
single cell suspensions by passing through different gauge needles. The cell suspension 
was centrifuged and resuspended in cold 2% FBS solution. Mononucleated cells were 
purified by centrifuging 6ml of cell suspension over 4ml of Ficoll-paque at 400g 4°C for 
30min. The buffy-coat was washed twice with 2%FBS 10-fold volumes of cell collection. 
Cells were suspended in cold PBS before transplantation, or suspended in 2% FBS 2mM 
EDTA for immunolabelling, and autoMACS sorting. 
2.2 Experimental Transplantation 
Cell transplantation was performed by injecting cells intrasplenically with an 
insulin needle into PHx (refer to Part I Section 2.4) mice or into mice that are 
subsequently treated with anti-fas antibody. Anti-Fas antibody treatment was 
administered by ip injection of 0.2mg/kg bw of Jo2 anti-Fas antibody (BD Pharmingen, 
San Diego, CA). When harvesting livers from mice, the mice were anaesthetized (refer to 
Part I Section 2.4) and then perfused with 10% neutral buffered formalin (Sigma; St 
Louis, MO) for paraffin embedding and immunohistochemical staining (refer to Part II 
Section 2.4) or 0.5% (w/v) glutaraldehyde (Sigma; St Louis, MO) for X-gal staining 
(refer to Part I Section 2.6), respectively. 
In the first series of experiment, 106 to 107 BM cells from Rosa26 were 
transplanted into PHx C57BL/6J (n=12). Three weeks later, the livers were harvested for 
X-gal staining. 
In the second series of experiment, 107 BM cells from Rosa26 mice (n=5) were 
transplanted into PHx C57BL/6J mice (n=4). Three weeks later, NPCs were isolated from 
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transplanted mice by a two-step collagenase perfusion method (refer to Part II Section 
2.3). The staining of NPCs were performed with C12FDG (Molecular Probes, Eugene, 
Oregon) for b-gal and followed with antibodies of Thy-1.2, CD34, and Sca-1 (refer to 
Part II Section 2.6) (BD PharMingen, San Diego, CA). 
In the third series of experiment, three weeks after transplanting 107 BM cells 
from MTnLacZ mice into PHx C57BL/6J mice (n=6), isolated 106 NPCs were 
transplanted into another PHx C57BL/6J recipient mice (n=4). After three weeks, 
transplanted mice were injected ip with 1mg/kg bw cadmium sulphate (Cd2+) 20 hours 
before the livers were harvested for X-gal staining.  
In the fourth series of experiment, 107 BM cells from C57BL/6J mice were 
transplanted into PHx ApoE-deficient mice (n=9). Three weeks later, isolated 106 NPCs 
were further transplanted to PHx ApoE-deficient mice (n=6). After another three weeks, 
Livers from NPCs-transplanted mice were harvested for immunohistochemical staining 
with anti-ApoE antibody (Santa Cruz, California). 
In the fifth series of experiment, 107 BM cells from FasLPR mice (n=6) were 
transplanted into ApoE-deficient mice (n=5) following immediate Fas antibody injection. 
Then Fas antibody injection was carried out once a week. Three weeks later, livers were 
harvested for anti-ApoE antibody staining. 
In the sixth series of experiment, 107 BM cells from FasLPR mice (n=5) were 
transplanted into PHx ApoE-deficient mice (n=3). Three weeks after transplantation, 
transplanted mice were given a weekly injection of Fas antibody for 6 weeks under daily 
immuosuppressive treatment with 2.5mg/kg bw FK506 (Tacrolimus) (Fujisawa Ireland 
Limited, Ireland). Serum from each transplanted mouse was collected retro-orbitally at 0 
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(before transplantation), 3, 6, and 9 weeks after transplantation. 9 weeks later, livers were 
harvested for immunohistochemical staining with anti-ApoE antibody. 
In the seventh of experiment, 106 BM cells from MTnLacZ were transplanted into 
PHx C57BL/6J (n=3). Three weeks after transplantation, mice were given an ip injection 
of 1mg/kg bw Cd2+ 20 hours prior to being killed. NPCs were isolated and staining for 
C12FDG and Thy-1 antibody staining. Pictures were taken with fluorescent microscope. 
In the eighth series of experiment, Thy-1+ and Thy-1- BM cells from Rosa26 mice 
were sorted using autoMACS (Miltenyi Biotec Inc., CA) with Thy-1 antibody labelling 
(refer to Part II Section 2.7). 105 sorted Thy-1+ or Thy-1- Rosa26 BM cells were 
transplanted into PHx C57BL/6J mice. Three weeks later, NPCs were isolated and further 
stained with C12FDG and Thy-1 antibody. Pictures were taken with fluorescent 
microscope. 
2.3 Isolation of NPCs from livers by using modified conventional two-step 
collagenase perfusion (Seglen 1973)  
Mice were anesthetized (refer to Part I Section 2.4). A dose of heparin at 
200unit/kg bw (Leo Pharmaceutical Products, Ballerup, Denmark) was also administered.  
Liver was perfused by infusing 50ml prewarmed (39°C) and oxygenated (5%CO2 and 
95%O2) Liver Perfusion Medium (GIBCO/BRL, Invitrogen, Grand Island, NY) and 
following 50ml Liver Digest Medium (GIBCO/BRL, Invitrogen, Grand Island, NY) via 
the portal vein at 3-5ml/min output for 15-20min. The digested liver was then transferred 
carefully to a bacteriological petri dish containing 10ml Liver Digest Medium where liver 
cells were released by tearing liver capsule and further incubated for another 30min at 
37°C with shaking. The cell suspension was centrifuged at 30g, 4ºC for 4min. The 
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supernatant was removed into a new tube, and cell pellet was discarded. This step was 
repeated for another three times. After the fourth differential centrifugation, the 
supernatant was centrifuged at 400g, 4°C for 5min; and supernatant was discarded. Cell 
pellet, composed mainly of NPCs, was resuspended and washed with 10ml 2% FBS 
twice. The cell suspension was kept on ice until use for transplantation or 
immunofluorescent staining. 
2.4 Immunohistochemical staining of liver paraffin sections  
Two blocks of liver samples from different lobes were randomly chosen for 
paraffin embedding.  The livers were sectioned at 3mm thickness using a microtome 
(Leica RM2135). Every 11th and 12th sections were selected and mounted on the 
polycine-coated slide. 6 pairs of sections were collected from each liver block. 
Paraffin sections were dewaxed by soaking sections in xylene for 10min, twice 
and then in 100% Ethanol for 10min, twice. The sections were hydrated by sequential 
soaking in 95% and 70% ethanol for 5min, and then distilled water for 5min three times. 
Endogenous peroxidase was quenched by soaking sections in 3% (v/v) H2O2 for 10min at 
room temperature (RT). Slides were washed in distilled water and equilibrated in PBS.  
All solutions hereafter were prepared in PBS. 
Sections were blocked with 2% (w/v) BSA (Sigma; St Louis, MO), 5% (v/v) 
rabbit serum (DAKO, Denmark) for 1hr, and then incubated with anti-ApoE antibody 
(1:200 dilution in 0.5% (w/v) BSA with 1% (v/v) rabbit serum) (Santa Cruz Biotech Inc, 
Santa Cruz, CA) for 14-16hrs at RT. After washing three times in PBS for 15min each, 
these slides were then incubated with 1:500 diluted biotinylated rabbit anti-goat antibody  
(DAKO, Denmark) for 30-45min at RT and washed three times with PBS before 
   65
incubating in streptavidin-HRP (1:500 dilution) (DAKO, Denmark) for 30-45min. After 
washing with PBS, the sections were incubated with DAB (Sigma; St Louis, MO), and 
counterstained with Mayer’s haematoxylin before dehydration of the reverse sequence of 
the hydration process described above. The sections were mounted with coverslips. 
2.5 Assay for serum ApoE in transplanted ApoE-deficient mice by western blot 
analysis  
As previously described (refer to Part I Section 2.10), 1ml serum from each 
sample was denatured and separated on 10% SDS-polyacrylamide gel. After separation, 
gel was electro-blotted onto a nitrocellulose membrane. The membrane was blocked in 
5% skim milk blocking buffer with shaking overnight at 4°C. Then membrane was 
incubated with goat anti-mouse ApoE (1:200 dilution), followed by biotin conjugated 
rabbit anti-goat antibody (1:5000 dilution), and HRP conjugated Neutravidin (1:10000 
dilution) for 1hr at RT, respectively. The membrane was incubated in the ECS and 
developed to X-ray film. 
2.6 Analysis of NPCs by fluoresence microscopy 
NPCs were stained for the presence of b-gal by incubating 106 cells in 200ml of 
prewarmed C12FDG substrate solution (33mM solution prepared by diluting 20mM stock 
solution with 2% FBS 2mM EDTA and 0.2mm filtered) at 37°C for 15-20min. The cells 
were then washed and resuspended in 200ml of cold 2% FBS 2mM EDTA. The cells were 
labelled with rat anti-mouse Thy-1.2, CD34 or Sca-1 (BD Pharmingen, San Diego, CA) 
by incubating with 1mg of biotin-conjugated antibodies for 20-30min at 4°C, washed and 
then incubated with RPE-conjugated streptavidin (1:20 dilution) (DAKO, Denmark) for 
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20-30min at 4°C. After washing cells with PBS, these cells were observed under 
fluorescent microscope with b-gal-  NPCs as negative controls. 
2.7 Isolation of Thy-1+ and Thy-1- cells from Rosa26 BM cells by MACS 
5×107 BM mononuclear cells was resuspended in 1ml of cold 2% FBS and labeled 
with 10mg FITC-conjugated Thy-1.2 (BD Pharmingen, San Diego, CA) for 30min at 4°C. 
After washing with cold 2% FBS, the cells were incubated with anti-FITC microbeads 
(BD Pharmingen, San Diego, CA) for 15-20min at 4°C. After washing with cold 2% FBS, 
cells were resuspended at 108 cells/500ml, and separated on autoMACS (Miltenyi Biotec 
Inc., CA) as per manufacturer’s protocol. 
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3 Results 
3.1 Donor BM cell engraftment in PHx mice 
To investigate BM cell engraftment in liver and its differentiation into 
hepatocytes, BM cells from Rosa26 mouse were transplanted into PHx C57BL6/J mice 
(n=15). Three weeks after transplantation, the transplanted mice were perfused and their 
livers were fixed with glutaraldehyde. Frozen liver sections were stained with X-gal 
staining for the presence of b-gal. Rosa26 BM-derived cells were detected in livers of 
PHx mice. Morphologically, no Rosa26 BM-derived hepatocytes were found in 
transplanted mice after three weeks. However, X-gal+ BM-derived cells were presented in 
the transplanted host liver as small cells. They could be a component of NPCs in 
transplanted liver. Since they were dispersed in the sinusoids, and smaller than host 
hepatocytes, suggesting that these were possibly Kupffer cells, endothelial cells, or 
hematopoietic cells (data not shown).  Occasionally, Rosa26 BM-derived cells could be a 
component of a small nodule in transplanted liver. The morphology of this nodule is 
similar to one type of cells, which was referred to as “small hepatocytes” (small 
hepatocyte-like progenitor cell or SHPC) (Gordon, Coleman et al. 2000; Gordon, 
Coleman et al. 2000). 
3.2 Characterization of BM-derived cells in recipient livers with surface markers  
To characterize BM-derived NPCs in mice, BM cells from Rosa26 mice were 
transplanted into PHx C57BL/6J mice (n=30). Three weeks after transplantation, NPCs 
were isolated by using a two-step collagenase perfusion method. These NPCs were 
double-labeled with C12FDG, a green fluorescent b-gal substrate to identify the Rosa26-
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derived cells, and biotin-conjugated Thy-1.2, CD34, and Sca-1 antibodies, respectively. 
Fluorescent microscope results showed that Rosa26 BM-derived cells with green 
fluorescence, and positive cells with red fluorescence labeled by Thy-1.2 (Figure 2a), 
CD34 (Figure 2b) or Sca-1 (Figure 2c) antibody are among transplanted NPCs. Among 
these cells, there were some of double-labeled cells that represent Rosa26 BM-derived 
cells coupled expression of Thy-1.2, CD34, or Sca-1. Morphologically, these cells are 
small in size (approximately 10-15mm). These data indicated that after transplantation, 
Thy-1.2, CD34, and Sca-1 positive donor BM cells were present in transplanted liver. 
Since hepatic stem/progenitor cells and hematopoietic stem cells share some common 
antigens, like Thy-1 (Petersen, Goff et al. 1998) and CD34 (Omori, Omori et al. 1997), it 
is possible that some of donor BM cells  were hepatic stem/progenitor cells.  
To test if there are BM-derived hepatic progenitor cells in recipient livers, BM 
cells from MTnLacZ mice were transplanted into PHx C57BL6/J mice (n=6). Three 
weeks after transplantation, NPCs were isolated from transplanted mouse livers primed 
with Cd2+ injection 24h prior to sacrifice. When NPCs were labeled with C12FDG and 
Thy-1.2 antibody, a population of Thy-1.2+ cells with b-gal+ nuclei was clearly evident by 
fluorescent microscope (Figure 3). Since facultative adult liver stem/progenitor cells 
(hepatic oval cells) are heterogeneous cells in different transitional stages of 
differentiation with some characteristics of mature hepatocytes (Sell and Ilic 1997), it is 
possible that the Thy-1 and nuclear b-gal co-expressing cells were BM-derived hepatic 
progenitor cells. 








                                                                                                                           
                                                                                                                                      
Figure 2 Immunofluorescent microscopy showed that Rosas26 BM-derived Thy-1+, 
CD34+, and Sca-1+ cells were found in NPCs from transplanted livers. 
Immunofluroscent pictures overlaying with transmission picture of b  galactosidase 
and antibody staining of isolated NPCs from Rosa26 BM transplanted C57BL/6J 
mice with b-gal substrate and fluorescent labeled antibody. BM-derived cells: green 
fluorescence; Thy-1+, CD34+, or Sca-1+: red fluorescence; BM-derived Thy-1+ 




Figure 1 X-gal staining demonstrates that engraftment of Rosa26 BM cells in recipient 
were present as small NPC cells (green-blue spots) and same section was stained using 
H&E. liver section from Rosa26 BM transplanted C57BL/6J mice were perfused and 
fixed in 0.5% glutaraldehyde. 12mm thickness of frozen sections were cut and performed 
with X-gal staining. Amplification 10´40 









3.3 Engrafted BM-derived cell differentiation into hepatocyte-like cells in second 
PHx recipients 
Our previous results suggested that BM-derived cells can engraft as NPCs in the 
transplanted livers and that some of these engrafted cells could be hepatic stem/progenitor 
cells. Therefore, to investigate if some of these BM-derived NPCs were hepatic 
progenitor cells that can differentiate into hepatocyte-like cells, BM cells from MTnLacZ 
mice were transplanted into PHx C57BL6/J mice (n=6). Three weeks later, NPCs from 
the transplanted livers were isolated and transplanted into a second series of PHx 
C57BL6/J mice (n=5). After another three weeks, these mice were treated with Cd2+ and 
their livers harvested. Since the donor BM cells were from a MTnLacZ transgenic mouse 
with a b-gal transgene and a nuclear localizing signal driven by a mouse metallothionein-I 
(MT-I) promoter, the Cd2+ pretreatment will induce a ten-fold enhanced nuclear 
     
 
Figure 3 Double staining with b-gal fluorescent substrate and Fluorescent labelled 
antibody showed that some of BM-derived Thy-1+ cells with MTnLacZ expression. 
NPCs are isolated from MTnLacZ mouse BM-transplanted livers. MTnLacZ BM-
derived cell: green fluorescence; Thy-1+: red fluorescence; MTnLacZ BM-derived and 
Thy-1+ cells: double labeled (white arrow). Amplification 10´40) 
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expression of b-gal in any BM-derived hepatocytes. Using X-gal staining on frozen liver 
sections, cells with b-gal+ nucleus were evident in NPCs transplanted mice (Figure 4). 
Morphologically, these BM-derived cells were hepatocyte-like cells i.e. about 15mm in 
diameter, and well integrated into hepatic plates. However, the frequency of BM-derived 
hepatocyte-like cells was rare, and less than 0.01%. 
To further verify if these BM-derived cells have some hepatocyte characters, this 
experiment was by using BM from C57BL/6J mice for transplantation into ApoE-
deficient mice. Serum ApoE a 34 kD glycoprotein is synthesized mainly in the liver and 
is a structural component of all lipoprotein particles other than low density lipoprotein 
(Shore and Shore 1973; Mahley, Innerarity et al. 1984). Immunohistochemical staining 
with anti-ApoE antibody demonstrated that ApoE+ cells were present in ApoE-deficient 
mouse livers after transplantation. These ApoE+ cells were morphologically similar to the 
host hepatocytes with the expected sizes of about 15-20 mm, and they were well 
integrated into the host hepatic cord (Figure 5). However, no ApoE was in the serum of 
the transplanted animals. Like the MTnLacZ BM transplantation, ApoE+ cells were rare 
and constituted less than 0.01% of hepatocytes. These experiments suggested that 
intrasplenic transplantation of BM cells into mice with a hepatic deficit can generate BM-
derived hepatocyte-like cells but with the caveat that liver regeneration time had to be 
extended by isolating BM-derived NPCs and transplanting in a second recipient. 
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Figure 5 BM-derived ApoE+ hepatocyte-like cells after BM transplant from C57BL/6J 
to ApoE-deficient mice. NPCs were isolated and transplanted into another ApoE-
deficient mouse. Immunohistochemical staining was performed in paraffin sections of 
NPCs transplanted liver with anti-ApoE antibody. BM-derived hepatocyte (black arrow) 




Figure 4 BM-derived MTnLacZ expressing hepatocyte-like cells after BM transplant from 
MTnLacZ mouse to C57BL/6J mice. NPCs were isolated and transplanted into another 
C57BL/6J mouse. NPC transplanted C57BL/6J liver harvested after injection of Cd2+. 12mm 
thick frozen sections were stained with X-gal and counterstained with eosin. MTnLacZ BM-
derived cell was positive in nucleus (blue) and morphologically fused into hepatic cord. 
Amplification 10´100 
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3.4 Derivation of hepatocyte-like cells from BM cells in mice with chronic hepatic 
deficiency induced by Fas-mediated apoptosis 
 To determine if BM cells can differentiate into hepatocytes if the micro-
environment is conducive to liver regeneration and persisted over an extended period of 
time, 107 BM mononuclear cells from FasLPR mice was transplanted intrasplenically into 
PHx ApoE-deficient mice (n=9). Three weeks later, mice were treated with a six weekly 
sublethal dose (0.2mg/kg bw) of a Fas-agonist antibody. In the seventh week, the 
experiment was terminated and livers were harvested. Serum from each transplanted 
mouse was taken at three weeks’ interval until termination of experiment.  
 At three weeks after transplantation, BM-derived ApoE+ hepatocyte-like cells 
were evident and were widely distributed as single hepatocyte-like cell (Figure 6). After 
six-weeks of Fas antibody administration, numerous colonies of BM-derived ApoE+ 
hepatocyte-like cells including binucleated ones were evident by immunohistochemical 
analysis (Figure 7, 8). Western blot analysis further confirmed the presence of ApoE+ 
hepatocytes by the presence of ApoE in the serum. ApoE protein was first detected three 
weeks after Fas treatment started and continued to increase with time (Figure 9). It was 
estimated that the level of serum ApoE in the transplanted ApoE deficient mice ranged 
from 2 to 16% of serum ApoE in wild-type mice (Figure 9). These data were consistent 
with the hypothesis that differentiation of BM cells into hepatocytes would require a 
chronic hepatic deficiency over an extended period of time. 
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Figure 6 BM-derived ApoE+ hepatocyte-like cells after BM cells from B6.MRL 
FASLPR transplanted to ApoE-deficient mice with immediate Fas antibody 
treatment, then following Fas antibody injection per week for three weeks. 
Immunohistochemical staining with anti-ApoE antibody was done in paraffin 
sections of transplanted liver. BM-derived hepatocyte-like cell (black arrow) was 
shown in brown color, and sections were counterstained with Mayer’s 






Figure 7 BM-derived ApoE+ hepatocyte-like cells after BM cells from B6.MRL 
FASLPR transplanted to ApoE-deficient mice following consecutive Fas antibody 
injection. After transplantation, three weeks later, sublethal dose of Fas antibody 
treatment once a week was carried out for 6 weeks. Immunohistochemical staining 
with anti-ApoE antibody was performed in paraffin sections. Dispersed and 
binucleated BM-derived hepatocyte-like cells (black arrows) were shown in a and b. 
Amplification 10´20 (a), 10´40 (b) 
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Figure 9 ApoE in serum was demonstrated by Western-blot after BM cells from 
B6.MRL FASLPR were transplanted to ApoE-deficient mice, following Fas 
antibody injection once a week for 6 three weeks. Sera from transplanted mice were 
fulfilled with immunoblotting by anti-ApoE antibody. ApoE protein is undetectable 
at 3 weeks after transplantation, but appeared at 6 and 9 weeks, representative 3 and 
6 weeks after Fas antibody treatment, respectively. 
   
 
Figure 8 Clusters of BM-derived ApoE+ hepatocyte-like cells after BM cells from 
B6.MRL FASLPR were transplanted to ApoE-deficient mice following consecutive 
antibody injection. After transplantation, three weeks later, weekly injection of sublethal 
dose of Fas antibody was performed for 6 weeks. Immunohistochemical staining with 
anti-ApoE antibody in paraffin sections demonstrated the clusters of BM-derived 
hepatocyte-like (in frame). Amplification 10´20 (left picture), 10´40 (right picture) 
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3.5 BM cell type in generating engrafted Thy-1+ cells in recipient livers  
To investigate if Thy-1+ or Thy-1- from BM could give rise to hepatic Thy-1+ 
cells, Thy-1+ and Thy-1- Rosa26 BM cells were isolated using autoMACS as described in 
Materials and Methods, and transplanted into PHx C57BL/6J mice. Both populations of 
BM cells generate NPCs that were both b-gal+ and Thy-1+ (Figure 10). It suggests that the 
characteristics of hepatic Thy-1+ cells could be different from Thy-1+ BM cell population. 





Figure 10 The pictures showed that BM-derived Thy-1+ cells (black arrows) in 
recipient NPCs were found in both transplantation of sorted Thy-1+ BM cells and 
sorted Thy-1-BM cells. Immunofluroscent picture overlaying with transmission 
picture of b  galactosidase and Thy-1 antibody staining of isolated NPCs from 
transplantation of MACS-sorted Rosa 26 BM Thy-1+ and Thy-1- cells. Green 
fluorescence: BM-derived cells; red fluorescence: Thy-1+ cells. Amplification 10´40 
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4 Discussion  
BM is a well characterized source of HSCs for generating hematopoietic lineages 
and reconstitution of the hematopoietic system (Weissman, Anderson et al. 2001). 
Recently, a series of experiments has demonstrated that there are cells in BM with the 
potential to differentiate not only into hematopoietic cells, but also into multiple non-
hematopoietic cell types (Clarke and Frisen 2001; Krause 2002). These demonstrations 
are particularly interesting from a therapeutic point of view. However, it is envisaged that 
therapeutic applications of BM in generating non-hematopoietic cells will be technically 
challenging as most reports describing BM-derived nonhematopoietic cells requires prior 
ablation and reconstitution of host BM. In fact, it was claimed that prior ablation and 
reconstitution of host BM and not direct transplantation of BM cells into the liver is 
necessary for derivation of hepatocytes from BM cells (Mallet, Mitchell et al. 2002; 
Wang, Montini et al. 2002). In contradiction to this claim, our study showed that direct 
injection of BM cells into the liver resulted in the engraftment and differentiation of BM 
cells into hepatocyte-like cells without prior ablation and reconstitution of host BM.  
The major reason for this discrepancy could be due to a procedural difference. In 
our study, BM cells from mice was transplanted into the liver immediately after PHx, 
while in other studies, BM cells were transplanted between 48 hours to 1 week after 
hepatic injury was induced (Mallet, Mitchell et al. 2002; Wang, Montini et al. 2002). This 
difference in timing has important implications for engraftment and differentiation of BM 
cells into hepatocytes.  It is known that within 24 hours after PHx, many growth factors 
and cytokines, including notable ones such as hepatocyte growth factor (HGF), 
interleukin-6 (IL-6), tumor necrosis factor-a (TNF-a) are rapidly elevated and then 
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declined in plasma (Michalopoulos and DeFrances 1997). During this time, transcription 
of a large number of immediate early genes are also initiated in liver and many of these 
transcriptions are initiated by four transcription factors, NFkB, STAT3, AP-1 and 
C/EBPb . Incidentally, these transcription factors are also known to play major roles in the 
initiation of liver regeneration (Fausto 2000). In addition, there is an extensive 
remodeling of the hepatic extracellular matrix after PHx (Fausto 2000). It is conceivable 
that these changes in the hepatic extracellular matrix will be more accommodating to the 
engraftment and integration of the transplanted BM cells than the structurally intact liver.  
Therefore, the microenvironment that is most optimal for BM engraftment and 
differentiation into hepatic lineage may be limited to the first 24 hours after initiation of 
liver injury. Since BM-derived hepatocytes cannot be found if transplantation of BM cells 
is carried out 48 hours after PHx (Mallet, Mitchell et al. 2002). 
In our study, we observed that the derivation of hepatocyte-like cells from BM 
cells appeared to involve two steps. Three weeks after transplantation, engrafted BM cells 
appeared as NPCs and not as hepatocytes. These BM-derived NPCs expressed Thy-1 and 
CD34, common surface markers of both adult hepatic progenitor cells and HSCs (Omori, 
Omori et al. 1997; Petersen, Goff et al. 1998; Baumann, Crosby et al. 1999; Domen and 
Weissman 1999; Weissman, Anderson et al. 2001). It is highly possible that this 
population of BM-derived cells is a mixed population of hepatic progenitor cells and 
HSCs. The engraftment of HSCs in the liver is not unexpected as the liver is also an 
important hematopoietic organ (Watanabe, Miyaji et al. 1996). Furthermore, it was 
reported that after PHx, regenerating liver producing erythropoietin and CSF making the 
microenvironment most suitable for HSCs engraftment and differentiation due to CSF 
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(Naughton, Gamba-Vitalo et al. 1982). Although these data suggest that some of these 
cells in the transplanted livers may be HSCs, we did not test the ability of these engrafted 
BM cells to reconstitute the hematopoietic system as this was beyond the scope of this 
study. Instead, we demonstrated that some of these engrafted BM cells might be hepatic 
progenitor cells as some of the engrafted BM-derived NPCs can generate hepatocyte-like 
cells when transplanted in a second PHx mouse. It has been previously demonstrated that 
BM is a source of hepatic oval cells that are generally accepted as adult liver stem cells 
(Petersen, Bowen et al. 1999).  Incidentally, these hepatic oval cells also express Thy-1 
and CD34 (Omori, Omori et al. 1997; Petersen, Goff et al. 1998). Therefore, like BM 
transplantation after ablation of the host hemantopoietic system (Morrison, Uchida et al. 
1995), intrasplenic injection of BM cells into PHx recipients similarly resulted in the 
formation of BM-derived hepatic progenitor cells. These BM-derived cells will 
differentiate into mature hepatocytes if the regenerative environment induced by 
hepatectomy either persisted sufficiently long enough or was extended by transplanting 
the cells into a second PHx animal. Further experiments should be done to study if BM-
derived Thy-1 or CD34 positive cells can differentiate into ApoE+ cells after second 
transplantation. 
Like other reports, our study also demonstrated that in spite of retransplanting 
BM-derived NPCs in a second PHx animal, the frequency of generating hepatocyte-like 
cells from BM cells was less than 0.01% (Mallet, Mitchell et al. 2002; Wagers, Sherwood 
et al. 2002; Wang, Montini et al. 2002). Therefore, for BM transplantation to be a viable 
option for liver replacement therapy, a strategy to expand these few cells to therapeutic 
level will have to be developed. Since liver regeneration is often mediated by 
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proliferation of mature hepatocytes rather than differentiation and proliferation of stem 
cells, the rare BM-derived hepatocytes can, in principle, be amplified to therapeutic 
replacement level.  To do so, two caveats will have to be fulfilled. One is that the BM-
derived hepatocyte-like cells must have a selective advantage over the host hepatocytes 
and the second is that the regenerative microenvironment must be of sufficient duration to 
sustain the relatively long process of generating hepatocytes from BM cells and the 
subsequent amplification of the rare BM-derived hepatocytes. In two seminal reports 
describing the derivation of hepatocytes from BM cells to effect a rescue of hepatic 
function in mouse models (Lagasse, Connors et al. 2000; Mallet, Mitchell et al. 2002), 
both caveats were fulfilled. In the first report, wild type BM cells were transplanted into 
FAH deficient mice after hematopoietic ablation. Generation of BM-derived hepatocytes 
begin only after 2-(2-nitro-4-trifluoro-methylbenzyol)-1,3-cyclohexanedione (NTBC) 
administration to the FAH deficient mice was halted to induce apoptosis of FAH deficient 
hepatocytes. This resulted in a chronic hepatic deficiency and a chronic regenerative 
microenvironment in the liver. In addition, the wild type BM-derived hepatocyes having a 
selective advantage over the FAH deficient hepatocytes were preferentially amplified to 
reach over 30% hepatic replacement level by 22 weeks and affecting a functional rescue 
of the FAH deficient mice. In the second report, unfractionated BM cells from transgenic 
mouse expressing Bcl-2 under the control of a liver-specific promoters were transplanted 
into lethally irradiated mice to reconstitute the host BM. Six weeks after BM 
transplantation, BM-derived hepatocytes with expression of Bcl-2 were generated and 
amplified in mouse model of hepatocytic apoptosis induced by weekly sublethal injection 
of Fas antibody. BM-derived Bcl-2 expressing hepatocytes which were protected from 
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Fas-induced hepatocyte apoptosis were selectively expanded to 0.05% to 0.8% of total 
liver cells after 8-rounds of Fas antibody injection. Using a similar approach, we 
transplanted BM cells from FasLPR mice with a Fas mutation into PHx ApoE-deficient 
mice. The transplanted animals were then treated with anti-Fas neutralizing antibody on a 
weekly regimen for six weeks. The purpose of this antibody treatment was two-fold. One 
was to induce Fas-mediated apoptosis of host hepatocytes to create a chronic hepatic 
deficiency and therefore, a chronic regenerating microenvironment. The other was to 
allow for the selective amplification of the anti-Fas insensitive BM-derived hepatocytes. 
After six weeks of Fas antibody treatment, groups of FasLPR BM-derived ApoE positve 
hepatocyte-like cells were detectable in ApoE-deficient recipient mice. The serum ApoE 
expression level in the transplanted ApoE-deficient mice was reached to 2 to 16% in 
comparison with serum ApoE in wild-type mice. These results suggest that hepatocyte-
like cells can be derived from BM cells without undergoing the deleterious procedure of 
hematopoietic reconstitution, and these BM-derived hepatocyte-like cells can be 
selectively expanded to achieve therapeutic efficacy with genetic and pharmacological 
manipulation, but without necessitating hematopoietic replacement in this process. 
Although the derivation of hepatocytes from BM cells is no longer controversial, 
the mechanism of its derivation and the source of the BM cells that generate hepatocytes 
remain contentious. There are currently three significantly different speculations on this 
phenomenon. One proposes that there could be an extra-hepatic progenitor cells in the 
blood that probably derived from BM (Sell 2001). The second proposes that certain 
population of HSCs may transdifferentiate from a mesodermal BM cells to an endodermal 
hepatic lineage (Forbes, Vig et al. 2002; Theise and Krause 2002). The third proposes that 
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a mesodermal BM cell acquires hepatic characteristics and functions via fusion with a 
hepatocyte (Terada, Hamazaki et al. 2002; Ying, Nichols et al. 2002; Vassilopoulos, 
Wang et al. 2003; Wang, Willenbring et al. 2003). In these  reports, the fusion cells 
appropriately activate expression of FAH gene, a hepatic specific gene that is silent in 
hematopoietic cells. They are mainly tetraploid with 80 XXYY (Vassilopoulos, Wang et 
al. 2003; Wang, Willenbring et al. 2003). However, from our data, it is hard to explain if 
BM-derived hepatocyte is of fusion event between a BM cell and a host hepatocyte. If 
fusion did occur between FasLPR BM cells and the host hepatocytes, there would be two 
possibilities. The fusion cells can acquire host character of expressing Fas, although they 
also have mutant Fas. These cells will lose their selective advantage and therefore 
progressive amplification during an extended period of selection. However, there could 
be other explainable possibilities. One is that fusion cells might aquire both donor and 
recipient Fas gene expression, but Fas functional performance on cell membrane in 
eliciting apoptotic cascade is incompetent. Since possibly Fas functional dimmer in active 
conformation is consisted of a wild type monomer and a mutant monomer. Another 
possibility is formally that the fusion cells may not express Fas through chromosomal 
reduction in which both host copies of Fas genes were lost. Other experimental 
investigation such as the observation that male BM cells can give rise to both diploid and 
polyploidy Y-chromosome hepatocytes within liver biopsies from sex-mismatched 
transplant (Forbes, Hodivala-Dilke et al. 2001), and the recent report that BM cell can 
differentiate into pancreatic endocrine beta cells, without evidence of cell fusion (Ianus, 
Holz et al. 2003) suggest that  cell fusion is still not an adequate explanation for the 
"transdifferentiation" of BM cell into hepatocyte. Extensive experiments should be done 
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to scrutinize if the different result could be stemmed from different experimental 
procedure. 
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Future study  
 Our study of mouse ES-derived AFP+ cells demonstrated that some of these cells 
could be hepatic progenitor cells with the potential to generate hepatocyte-like cells in 
vivo. However, to extend this study to human ES cells and derive human hepatic 
progenitors for clinical applications, our strategy in isolating AFP+ cells will not work. 
Nevertheless, the mouse ES-derived AFP+ cells will be useful in identifying specific 
surface markers for hepatic progenitor cells and given the general conservation of 
important surface antigens between mouse and human cells, it is likely that some of the 
markers will also be specific for human ES cell-derived hepatic progenitor cells. This 
then provides the possibility of generating and isolating human ES cell-derived hepatic 
progenitor cells in vitro for regenerative therapy. 
In our BM transplantation study and work by others, the derivation of hepatocyte-
like cells from BM is undisputable. However the identity of BM cell giving rise to 
hepatocyte and the mechanism by which BM cell is transformed into a hepatocyte remain 
unknown and controversial.  Some of the issues that will have to be addressed in the 
future includes: 
1. Characterization of the subpopulation of BM cells that engrafted in the 
PHx liver,   
2. The process by which BM cells engrafted in the liver either directly as 
NPCs or through differentiation process first to form NPCs and then 
engraftment, 
3. Identity of the BM cell that eventually transforms into hepatocyte-like 
cells, 
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4. The mechanism through which BM cell transforms into hepatocyte: fusion, 
transdifferentiation or BM-localized hepatic progenitor cell  
Issues 1 to 3 can be directly tested using our experimental procedure of direct 
intrasplenic transplantation of BM cells into the liver, but will not be as tractable using 
hematopoietic reconstitution. A recent study demonstrated that BM cell acquires hepatic 
characteristics and functions via fusion with host hepatocyte and this fused cell can rescue 
FAH-deficient mice. However, such a proposal will not be consistent with this present 
study. As the BM cells used in our study are Fas-deficient (FasLPR mouse) while the host 
hepatocytes were Fas-wildtype, fusion cells will be Fas-heterozygous and possibly 
therefore be sensitive to anti-Fas mediated apoptosis. Instead, we observed a preferential 
expansion of BM-derived hepatocytes over the host hepatocytes after prolonged anti-Fas 
therapy. 
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Summary 
It is evident from our data that hepatocyte-like cells can be generated in vivo from 
differentiated ES and from BM cells. ES cell-derived hepatic progenitor cells can be 
easily selected from a population of differentiated ES cells by co-expressing GFP gene 
with AFP. This procedure might abolish the potential side effects of generating ES cell-
derived tumors. These hepatic progenitors are responsive to in vivo regenerating cues and 
develop into hepatocyte-like cells after transplantation. Transplantation of a small amount 
of ES cell-derived progenitor cells can achieve a measurable level of some liver functions 
in deficient mice in specific liver functions. Our approach in isolating of highly enriched 
hepatic progenitors from ES cells could be expanded to include isolation of different 
lineage-restricted hepatic progenitors and will allow the dissection of the cellular and 
molecular processes accompanying the various differentiation stages of the hepatocytes. 
It may serve as a platform for further manipulations with growth and differentiating 
factors that eventually enable the ES cells to be used as tool in basic hepatic research and 
regenerative medicine. Like generation of hepatocyte-like cells from differentiated ES, 
BM cells can give rise to hepatocyte-like cells after hematopoietic replacement. However, 
our data showed that host hematopoietic reconstitution by donor BM cells after irradiation 
is not an obligatory procedure in derivation of hepatocyte-like cells from BM. The 
demonstration that BM cells have a hepatic differentiation potential is particular 
interesting from a regenerative medicine point of view, but the procedure of host BM 
reconstitution is too severe for most therapeutic applications and will limit its application. 
However, our results suggest that a therapeutic strategy using BM cells without host BM 
reconstitution for regenerating hepatocytes  is highly conceivable. 
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